

Express Mail No. EF378139601US

METHODS OF TREATING NUCLEAR FACTOR-KAPPA B MEDIATED  
DISEASES AND DISORDERS

## METHODS OF TREATING NUCLEAR FACTOR-KAPPA B MEDIATED DISEASES AND DISORDERS

### CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application claims benefit of priority from United States provisional  
application serial number 60/268,203, filed February 12, 2001.

### FIELD OF THE INVENTION

10 The present invention provides methods of treating a disease or a disorder  
responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising  
administering to patients in need thereof a sulfonylaminocarbonyl derivative, or a  
pharmaceutically acceptable salt thereof.

### BACKGROUND OF THE INVENTION

15 Inhibition of nuclear factor-kappa B ("NF- $\kappa$ B") transcription factor-  
mediated activity would provide valuable methods of treating a disease or a  
disorder afflicting millions of people worldwide. This is so because NF- $\kappa$ B  
mediates transcription of a large number of genes involved in the production of  
20 pro-inflammatory cytokines and other biomolecules intimately involved in the  
etiology of many diseases and disorders for which no completely effective  
treatment is available. Noteworthy among the diseases and disorders thought to be  
responsive to the inhibition of NF- $\kappa$ B are rheumatoid arthritis and osteoarthritis,  
autoimmune diseases, psoriasis, asthma, cardiovascular diseases such as, for  
25 example, atherosclerosis, acute coronary syndromes including myocardial  
infarction and unstable angina, and congestive heart failure, Alzheimer's disease,  
multiple sclerosis, cancer, type 2 diabetes, metabolic syndrome X, and  
inflammatory bowel disease ("IBD"). These diseases and disorders are among the  
most prevalent in society today and cause untold suffering and death

Current methods of treatment of the above mentioned diseases and disorders are unsatisfactory, as they typically require surgical alteration or removal of the affected body part or the use of pharmaceuticals that treat symptoms, without stopping or, ideally, reversing the underlying disease process.

5 For example, while there are many marketed agents that modify risk factors for atherosclerosis (e.g., reduction of plasma lipids and anti-hypertensive agents), there are no therapies that directly modify the atherosclerosis process itself. Further, more than 60% of all coronary artery disease cannot be explained on the basis of traditional risk factors alone.

10 One explanation for the lack of success of current treatments for the above-mentioned diseases is that multiple gene products are probably involved in each disease or disorder. Typical drug therapies target only one of these gene products. Also, many of the current drugs used to treat these diseases and disorders exhibit undesirable side effects such as, for example, the gastric ulceration observed with many nonsteroidal anti-inflammatory drugs ("NSAIDs")

15 used to treat arthritis. Disadvantages of surgical methods of treating these diseases and disorders include the use of highly invasive procedures that cause pain, scarring, and sometimes infection.

In contrast, inhibition of NF- $\kappa$ B is potentially capable of halting, and even reversing, the progression of the underlying diseases and disorders mentioned

20 above. Inhibitors of NF- $\kappa$ B are effective by virtue of their ability to prevent, block, and even halt a common key step in the activation of the genes involved in the production of a number of mediators of these diseases and disorders. In other words, NF- $\kappa$ B inhibitors work upstream to inhibit the production of multiple pro-

25 inflammatory mediators, whereas traditional drug treatment regimens are less effective, perhaps because they work downstream and typically target only one of these mediators.

Nuclear factor- $\kappa$ B is a family of heterogeneous protein dimers that act as sequence-specific transcription factors in the activation of a large number of genes

30 in response to inflammation, viral or bacterial infections, or other biological diseases and disorders requiring rapid reprogramming of gene expression. NF- $\kappa$ B is normally found sequestered in the cytoplasm in an inactive form bound to an inhibitory protein, namely the inhibitor of  $\kappa$ B ("I $\kappa$ B"). I $\kappa$ B is thus bound with

NF- $\kappa$ B to form an NF- $\kappa$ B-I $\kappa$ B complex, but NF- $\kappa$ B is rapidly converted to an active form via signaling processes that are still being elucidated.

NF- $\kappa$ B is found in virtually all cell types including T-lymphocytes, monocytes, macrophages, endothelial cells, and smooth muscle cells. In response to a stimulus such as, for example, an inflammatory cytokine, a reactive oxygen intermediate, or a lipopolysaccharide from a microorganism, the I $\kappa$ B component of the NF- $\kappa$ B-I $\kappa$ B complex is cleaved via a process comprising the sequential steps of phosphorylation, polyubiquitinylation, and degradation. Degradation of the modified I $\kappa$ B protein exposes the nuclear localization sequence on NF- $\kappa$ B, allowing translocation of NF- $\kappa$ B to the nucleus of the cell, where it binds to its target gene to initiate transcription.

Among the genes to which NF- $\kappa$ B binds in order to initiate transcription are genes expressing pro-inflammatory cytokines. These pro-inflammatory cytokines include tumor necrosis factor-alpha ("TNF- $\alpha$ "), interleukin-1 ("IL-1"), IL-6, IL-8, intercellular adhesion molecule-1 ("ICAM-1"), vascular cell adhesion molecule-1 ("VCAM-1"), E-selectin, monocyte chemotactic protein-1 ("MCP-1"), inducible nitric oxide synthase, tissue factor, and cyclooxygenase-2 ("COX-2"). The result of the transcriptional activation of genes expressing pro-inflammatory cytokines is a tissue-localized production of these cytokines, and the beginning or exacerbation of an inflammatory process in the affected tissue.

The present invention provides a method of using a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, to treat diseases and disorders known to be responsive to the inhibition of NF- $\kappa$ B.

The following United States patents disclose methods of using certain sulfonylaminocarbonyl derivatives as inhibitors of the enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT) for treating hypercholesterolemia and atherosclerosis:

United States Patent Number 5,245,068 and its Divisional 5,384,328;  
United States Patent Number 5,214,206 and its Divisional 5,288,757;  
United States Patent Number 5,254,715 and its Divisional 5,336,690;  
United States Patent Number 5,198,466 and its Divisional 5,364,882;  
United States Patent Number 5,491,172 and its Divisional 5,633,287; and  
United States Patent Number 5,254,589 and its Continuation 5,981,595.

United States Patent Number 6,093,744 discloses methods of using certain sulfonylaminocarbonyl derivatives as ACAT inhibitors for regulating plasma cholesterol levels and lowering serum or plasma Lp(a) levels, and for treating hypercholesterolemia, atherosclerosis, peripheral vascular diseases, and restenosis.

5 United States Patent Number 6,117,909 discloses methods of using certain sulfonylaminocarbonyl derivatives as ACAT inhibitors for lowering serum or plasma Lp(a) levels, and treating cerebrovascular diseases, including stroke, peripheral vascular diseases, and restenosis.

10 United States Patent Number 6,124,309 and its Divisional Patent Numbers 6,143,755 and 6,093,719 disclose methods of using a sulfonylaminocarbonyl derivative as an ACAT inhibitor in combination with an HMG-CoA reductase inhibitor for restoring endogenous vascular endothelium-dependent activities including improving the normal dilation capacity of the endothelium, inducing vasodilation to modulate vascular tone and blood flow, 15 decreasing the adherent properties of the blood vessel walls, and decreasing the coagulation of platelets, and for treating myocardial infarction and acute ischemic syndromes including angina pectoris, coronary artery disease, hypertension, cerebrovascular accidents, transient ischemic attacks, chronic obstructive pulmonary disease, chronic hypoxic lung disease, pulmonary hypertension, renal 20 hypertension, chronic renal disease, microvascular complications of diabetes, and vaso-occlusive complications of sickle cell anemia.

As NF- $\kappa$ B is involved in the initiation and progression of inflammatory disease, a screening assay which provides a method for rapidly screening large numbers of compounds in vitro for their ability to inhibit NF- $\kappa$ B mediated 25 transcription of a gene would be a valuable tool. Such a screening assay would be an important step in the pursuit of compounds to treat diseases responsive to inhibition of NF- $\kappa$ B.


We have now discovered the ability of certain sulfonylaminocarbonyl derivatives to inhibit NF- $\kappa$ B mediated transcription. Accordingly, the present 30 invention provides a method of treating a disease or a disorder responsive to inhibition of NF- $\kappa$ B, comprising administering to patients in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof. All that is needed to practice the present invention is to administer to said patients

a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, from 1 to 6 times daily for the treatment of rheumatoid arthritis, osteoarthritis, autoimmune diseases, psoriasis, asthma, cardiovascular diseases such as, for example, atherosclerosis, acute coronary syndromes including myocardial infarction and unstable angina, and congestive heart failure, Alzheimer's disease, multiple sclerosis, cancer, type 2 diabetes, metabolic syndrome X, and inflammatory bowel disease. Determination of a proper dosage and form of administration of a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, for use in the method of the present invention is well within the abilities of one of ordinary skill in the pharmaceutical and medical arts.

### SUMMARY OF THE INVENTION

The present invention provides a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof.

The sulfonylaminocarbonyl derivatives disclosed in United States Patent Number 5,491,172 and its Divisional 5,633,287, which are both hereby incorporated herein by reference, are useful in the present invention. Thus, one embodiment of the present invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative of Formula I



or a pharmaceutically acceptable salt thereof, wherein:

X and Y are selected from oxygen, sulfur, and  $(\text{CR}'\text{R}'')_n$ , wherein n is an integer

of from 1 to 4 and R' and R'' are each independently hydrogen, alkyl,

alkoxy, halogen, hydroxy, acyloxy, cycloalkyl, phenyl optionally substituted or R' and R'' together form a spirocycloalkyl or a carbonyl;

with the proviso at least one of X and Y is  $-(CR'R'')_n$ - and with the further proviso when X and Y are both  $(CR'R'')_n$  and R' and R'' are hydrogen and n is

5 one, R<sub>1</sub> and R<sub>2</sub> are aryl;

R is hydrogen, a straight or branched alkyl of from 1 to 8 carbon atoms or benzyl; R<sub>1</sub> and R<sub>2</sub> are each independently selected from:

(a) phenyl or phenoxy each of which is unsubstituted or is substituted with from 1 to 5 substituents selected from:

10 phenyl,

an alkyl group having from 1 to 6 carbon atoms and which is straight or branched,

an alkoxy group having from 1 to 6 carbon atoms and which is straight or branched;

15 phenoxy,

hydroxy,

fluorine,

chlorine,

bromine,

20 nitro,

trifluoromethyl,

-COOH,

-COOalkyl, wherein alkyl has from 1 to 4 carbon atoms and is straight or branched, and

25  $-(CH_2)_pNR_3R_4$ , wherein p is zero or one, and each of R<sub>3</sub> and R<sub>4</sub> is

selected from hydrogen or a straight or branched alkyl group having 1 to 4 carbon atoms;

(b) 1- or 2-naphthyl unsubstituted or substituted with from 1 to 3 substituents selected from:

30 phenyl,

an alkyl group having from 1 to 6 carbon atoms and which is straight or branched,

an alkoxy group having from 1 to 6 carbon atoms and which is straight or branched;

hydroxy,

phenoxy,

5 fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

10 -COOH,

-COOalkyl, wherein alkyl has from 1 to 4 carbon atoms and is straight or branched, and

-(CH<sub>2</sub>)<sub>p</sub>NR<sub>3</sub>R<sub>4</sub>, wherein p, R<sub>3</sub> and R<sub>4</sub> have the meanings defined above;

(c) arylalkyl;

15 (d) a straight or branched alkyl chain having from 1 to 20 carbon atoms and which is saturated or contains from 1 to 3 double bonds; and


(e) adamantyl or a cycloalkyl group wherein the cycloalkyl moiety has from 3 to 6 carbon atoms;

with the provisos:

20 (i) where X is (CH<sub>2</sub>)<sub>n</sub>, Y is oxygen, and R<sub>1</sub> is a substituted phenyl, then R<sub>2</sub> is a substituted phenyl;

(ii) where Y is oxygen, X is (CH<sub>2</sub>)<sub>n</sub>, R<sub>2</sub> is phenyl or naphthyl, then R<sup>1</sup> is not a straight or branched alkyl chain; and

(iii) the following compounds are excluded:

X	Y	R	R <sub>1</sub>	R <sub>2</sub>
CH <sub>2</sub>	O	H	(CH <sub>2</sub> )CH <sub>3</sub>	Ph
CH <sub>2</sub>	O	H	CH <sub>3</sub>	Ph
CH <sub>2</sub>	O	H		i-Pr



with the further proviso that compounds selected from the group consisting of:

Sulfamic acid [1-oxo-3-[2,4,6-tris(1-methylethyl)phenyl]propyl]-  
2,6-bis(1-methylethyl)phenyl ester,  
5 Sulfamic acid [fluoro[2,4,6-tris(1-methylethyl)phenyl]acetyl]-  
2,6-bis(1-methylethyl)phenyl ester, and  
Sulfamic acid [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-  
2,6-bis(phenyl)phenyl ester  
are excluded.

10 Other embodiments are invention methods of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative of Formula I:

wherein R<sub>1</sub> is phenyl or is phenyl disubstituted in the 2,6-positions;


15 wherein R<sub>2</sub> is phenyl or is phenyl disubstituted in the 2,6-positions;

wherein each of R<sub>1</sub> and R<sub>2</sub> is phenyl;

wherein each phenyl is disubstituted in the 2,6-position;

wherein R<sub>1</sub> is phenyl disubstituted in the 2,6-positions and R<sub>2</sub> is phenyl  
trisubstituted in the 2,4,6-positions;

20 wherein R<sub>1</sub> is 2,6-bis(1-methylethyl)phenyl and R<sub>2</sub> is  
2,6-bis(1-methylethyl)phenyl or 2,4,6-tris(1-methylethyl)phenyl; or  
wherein one of R<sub>1</sub> and R<sub>2</sub> is the group



25 wherein t is zero or 1 to 4; w is zero or 1 to 4 with the proviso that the sum of t and w is not greater than 5; R<sub>5</sub> and R<sub>6</sub> are each independently selected from  
30 hydrogen or alkyl having from 1 to 6 carbon atoms, or when R<sub>5</sub> is hydrogen, R<sub>6</sub>  
can be selected from the groups defined for R<sub>7</sub>; and R<sub>7</sub> is phenyl or phenyl  
substituted with from 1 to 3 substituents selected from a straight or branched alkyl

group having from 1 to 6 carbon atoms, straight or branched alkoxy group having from 1 to 6 carbon atoms, phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, -COOH, COOalkyl wherein alkyl has from 1 to 4 carbon atoms, or  $-(CH_2)_pNR_3R_4$  wherein P,  $R_3$  and  $R_4$  have the meanings defined above.

5 Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative of Formula I, or a pharmaceutically acceptable salt thereof, wherein: X is oxygen, sulfur or  $(CR'R'')_n$ ;

10 Y is oxygen, sulfur or  $(CR'R'')_n$ , with the proviso that at least one of X or Y is  $(CR'R'')_n$  wherein n is an integer of from 1 to 4 and  $R'$  and  $R''$  are each independently hydrogen, straight or branched alkyl of from 1 to 6 carbons, optionally substituted phenyl, halogen, hydroxy, alkoxy, acyloxy, cycloalkyl, or  $R'$  and  $R''$  taken together form a carbonyl or a spirocycloalkyl group of from 3 to 10 carbons;

15 R is hydrogen;

$R_1$  is phenyl optionally substituted, straight or branched alkyl of from 1 to 10 carbon atoms, cycloalkyl of from 3 to 10 carbon atoms; and

20  $R_2$  is phenyl optionally substituted, straight or branched alkyl of from 1 to 10 carbon atoms, cycloalkyl of from 3 to 8 carbon atoms, phenoxy optionally substituted with the proviso that only if X is  $(CR'R'')_n$  can  $R_1$  be optionally substituted phenoxy and only if Y is  $(CR'R'')_n$  can  $R_2$  be optionally substituted phenoxy, and with the further proviso that at least one of  $R_1$  and  $R_2$  is optionally substituted phenyl or phenoxy.

25 Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative of Formula I, or a pharmaceutically acceptable salt thereof, wherein: X is oxygen;

30 Y is  $(CR'R'')_n$  wherein n is an integer of from 1 to 2;

R is hydrogen;

R<sub>1</sub> is optionally substituted phenyl;

R<sub>2</sub> is optionally substituted phenyl or phenoxy, straight or branched alkyl of from 1 to 10 carbons, or cycloalkyl of from 3 to 10 carbons; and

R' and R'' are each independently hydrogen, straight or branched alkyl of from 1 to 6 carbons, optionally substituted phenyl, halogen, hydroxy, alkoxy, acyloxy, cycloalkyl, or R' and R'' taken together form a carbonyl or a spirocycloalkyl.

Other embodiments of the invention are methods of treating a disease or a disorder responsive to inhibition of nuclear factor-κB transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative of Formula I, or a pharmaceutically acceptable salt thereof, wherein one of R<sub>1</sub> and R<sub>2</sub> is phenyl; wherein one of R<sub>1</sub> and R<sub>2</sub> is substituted phenyl; or wherein one of R<sub>1</sub> and R<sub>2</sub> is phenyl disubstituted in the 2,6-positions.

Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor-κB transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative of Formula I, or a pharmaceutically acceptable salt thereof, wherein both R<sub>1</sub> and R<sub>2</sub> are phenyl disubstituted in the 2,6-positions.

In another embodiment of the invention, the method uses a sulfonylaminocarbonyl derivative of Formula I, or a pharmaceutically acceptable salt thereof, wherein R<sub>1</sub> is phenyl disubstituted in the 2,6-positions and R<sub>2</sub> is phenyl trisubstituted in the 2,4,6-positions.

Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor-κB transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative of Formula I, or a pharmaceutically acceptable salt thereof, selected from:

(1,2,3,4-Tetrahydro-naphthalene-2-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester;

[Bis-(4-chloro-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester;

(Bromo-phenyl-acetyl)-sulfamic acid 2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-hydroxy-2,6-diisopropyl-phenyl ester;

Methyl-[(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester;

5 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-nitro-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-fluoro-2,6-diisopropyl-phenyl ester;

10 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-dimethoxy-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-amino-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,4,6-trimethoxy-phenyl ester;

15 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-tert-butyl-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-acetyl-2-isopropyl-phenyl ester;

20 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-methoxy-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-dichloro-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid dodecyl ester;

25 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-bromo-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-methyl-phenyl ester;

[1-(4-Dimethylamino-phenyl)-cyclopentanecarbonyl]-sulfamic acid 2,6-diisopropyl-phenyl ester;

30 [1-(4-Nitro-phenyl)-cyclopentanecarbonyl]-sulfamic acid 2,6-diisopropyl-phenyl ester;

3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy}-benzoic acid methyl ester;

- Sulfamic acid (phenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;  
Sulfamic acid[[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester;
- 5 Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester;
- Sulfamic acid [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,4,6-tris(1-methylethyl)phenyl ester;
- 10 Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]acetyl]-2,4,6-tris(1-methylethyl)phenyl ester;
- Sulfamic acid[adamantaneacetyl]-2,6-bis[1-methylethyl)phenyl ester,  
Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester-sodium salt;
- 15 Sulfamic acid[[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester-sodium salt;
- Sulfamic acid (decanoyl)-2,6-bis-(1-methylethyl)phenyl ester;  
Sulfamic acid (dodecanoyl)-2,6-bis-(1-methylethyl)phenyl ester;  
2,6-Bis(1-methylethyl)-N-[[[2,4,6-tris(1-methylethyl)phenyl]methyl]-sulfonyl]benzeneacetamide;
- 20 2,6-Bis(1-methylethyl)-N-[[[2,4,6-tris(1-methylethyl)phenyl]methyl]-sulfonyl]benzeneacetamide-sodium salt;
- 2,6-Bis(1-methylethyl)phenyl[[[2,4,6-tris(1-methylethyl)phenyl]methyl]-sulfonyl]carbamate;
- 2,6-Bis(1-methylethyl)phenyl[[[2,4,6-tris(1-methylethyl)phenyl]methyl]-sulfonyl]carbamate-sodium salt;
- 25 Sulfamic acid (1-oxo-3,3-diphenylpropyl)-2,6-bis(1-methylethyl)phenyl ester;
- Sulfamic acid [2,6-dichlorophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester,
- Sulfamic acid [2,6-dichlorophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester-sodium salt;
- 30 Sulfamic acid trans-[(2-phenylcyclopropyl)carbonyl]-2,6-bis(1-methylethyl)phenyl ester;

- Sulfamic acid [2,5-dimethoxyphenyl(acetyl)]-2,6-bis(1-methylethyl)-phenyl ester;
- Sulfamic acid [2,4,6-trimethoxyphenyl(acetyl)]-2,6-bis(1-methylethyl)-phenyl ester;
- 5 Sulfamic acid [2,4,6-trimethylphenyl(acetyl)]-2,6-bis(1-methylethyl)-phenyl ester;
- Sulfamic acid [2-thiophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;
- Sulfamic acid [3-thiophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;
- Sulfamic acid [2-methoxyphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl
- 10 ester;
- Sulfamic acid (oxophenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;
- Sulfamic acid [2-trifluoromethylphenyl(acetyl)]-2,6-bis(1-methylethyl)-phenyl ester;
- Sulfamic acid (1-oxo-2-phenylpropyl)-2,6-bis(1-methylethyl)phenyl ester;
- 15 Sulfamic acid (cyclopentylphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;
- Sulfamic acid (cyclohexylacetyl)-2,6-bis(1-methylethyl)phenyl ester;
- Sulfamic acid (diphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;
- Sulfamic acid (triphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;
- 20 Sulfamic acid [(1-phenylcyclopentyl)carbonyl]-2,6-bis(1-methylethyl)-phenyl ester;
- Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl)-2,6-bis(1-methylethyl)phenyl ester;
- Sulfamic acid (1-oxo-2-phenylbutyl)-2,6-bis(1-methylethyl)phenyl ester;
- 25 Sulfamic acid (cyclohexylphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;
- Sulfamic acid (1-oxo-2,2-diphenylpropyl)-2,6-bis(1-methylethyl)phenyl ester;
- Sulfamic acid [(9H-fluoren-9-yl)carbonyl]-2,6-bis(1-methylethyl)phenyl
- 30 ester;
- Sulfamic acid (1-oxo-3-phenylpropyl)-2,6-bis(1-methylethyl)phenyl ester;
- Sulfamic acid [1-oxo-3-[2,4,6-tris(1-methylethyl)phenyl]-2-propenyl]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [(acetyloxy)[2,4,6-tris(1-methylethyl)phenyl]acetyl]-  
2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [hydroxy[2,4,6-tris(1-methylethyl)phenyl]acetyl]-  
2,6-bis(1-methylethyl)phenyl ester;

5 Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl)-  
2,6-bis(1-methylethyl)phenyl ester sodium salt;


Sulfamic acid [[2,4,6-tris(1-methylethyl)phenoxy]acetyl]-  
2,6-bis(1-methylethyl)phenyl ester; and

10 Sulfamic acid [[2,6-bis(1-methylethyl)phenoxy]acetyl]-  
2,6-bis(1-methylethyl)phenyl ester.

Another embodiment of the invention is a method of treating a disease or a  
disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors,  
comprising administering to a patient in need thereof a sulfonylaminocarbonyl  
derivative of Formula I named sulfamic acid [[2,4,6-tris(1-  
15 methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester, or a  
pharmaceutically acceptable salt thereof.

Another embodiment of the invention is a method of treating a disease or a  
disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors,  
comprising administering to a patient in need thereof a sulfonylaminocarbonyl  
20 derivative of Formula I named sulfamic acid [[2,4,6-tris(1-  
methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester.

The sulfonylaminocarbonyl derivatives disclosed in United States Patent  
Number 6,093,744, which is hereby incorporated herein by reference, are also  
25 useful in the present invention. Thus, another embodiment of the present invention  
is a method of treating a disease or a disorder responsive to inhibition of nuclear  
factor- $\kappa$ B transcription factors, comprising administering to a patient in need  
thereof a sulfonylaminocarbonyl derivative of Formula II



II

or a pharmaceutically acceptable salt thereof, wherein:

R<sup>1</sup> is hydrogen, alkyl, or alkoxy;


R<sup>2</sup> to R<sup>5</sup> are alkyl, alkoxy, or unsubstituted or substituted phenyl; and

R<sup>6</sup> is -CN,


- 5           -(CH<sub>2</sub>)<sub>0-1</sub>-NR<sup>7</sup>R<sup>8</sup>,  
               -O-(CH<sub>2</sub>)<sub>1-10</sub>-Z, wherein Z is -NR<sup>9</sup>R<sup>10</sup>, OR<sup>1</sup>, or CO<sub>2</sub>R<sup>1</sup>,  
               -OC(=O)R<sup>11</sup>,  
               -SR<sup>11</sup>,  
               -SCN,  
 10           -S(CH<sub>2</sub>)<sub>1-10</sub>Z,  
               -S(O)<sub>1-2</sub>R<sup>12</sup>, wherein R<sup>12</sup> is hydroxy, alkoxy, alkyl, (CH<sub>2</sub>)<sub>1-10</sub>Z or  
                   NR<sup>7</sup>R<sup>8</sup>,  
               -C(=O)XR<sup>11</sup>, or  
               -CH<sub>2</sub>-R<sup>13</sup>, wherein R<sup>13</sup> is (CH<sub>2</sub>)<sub>0-5</sub>-Y-(CH<sub>2</sub>)<sub>0-5</sub>Z, or alkyl of from 1 to  
 15           20 carbons with from 1-3 double bonds, which alkyl is optionally  
               substituted by one or more moieties selected from -CN, NO<sub>2</sub>,  
               halogen, OR<sup>1</sup>, NR<sup>9</sup>R<sup>10</sup>, and CO<sub>2</sub>R<sup>1</sup>;

wherein R<sup>7</sup> and R<sup>8</sup> are each independently selected from:

- hydrogen, at least one of R<sup>7</sup> and R<sup>8</sup> is other than hydrogen;  
 20           -(CH<sub>2</sub>)<sub>1-10</sub>Z, wherein Z is as defined above and R<sup>9</sup> and R<sup>10</sup> are each  
               independently selected from hydrogen, alkyl, and unsubstituted or  
               substituted phenyl, or  
               R<sup>9</sup> and R<sup>10</sup> are taken together with the nitrogen to which they are  
               attached to form a ring selected from:







wherein R<sup>14</sup>, R<sup>15</sup>, and R<sup>16</sup> are each independently selected from hydrogen, alkyl, and unsubstituted or substituted phenyl;

5 -C(=Q)XR<sup>11</sup>, wherein X is a bond or NH wherein Q is O or S, R<sup>11</sup> is hydrogen, alkyl, unsubstituted or substituted phenyl;


-(CH<sub>2</sub>)<sub>0-5</sub>-Y-(CH<sub>2</sub>)<sub>0-5</sub>Z, wherein Z is as defined above and Y is phenyl or a bond;

-C(=O)-CR<sup>17</sup>R<sup>18</sup>Z;

10 -C(=O)NHCR<sup>17</sup>R<sup>18</sup>Z, wherein R<sup>17</sup> and R<sup>18</sup> are each independently hydrogen, alkyl, phenyl, substituted phenyl, or the side chain of a naturally occurring amino acid;

-S(O)<sub>1-2</sub>R<sup>19</sup>, wherein R<sup>19</sup> is alkyl, unsubstituted or substituted phenyl, naphthyl, or a heteroaromatic ring, or NR<sup>9</sup>R<sup>10</sup>; or

15 R<sup>7</sup> and R<sup>8</sup> are taken together with the nitrogen to which they are attached to form a ring selected from:



20

wherein R<sup>14</sup>, R<sup>15</sup>, and R<sup>16</sup> are as above, with the proviso that compounds selected from:

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-formyl-  
2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-cyano-vinyl)-  
2,6-diisopropyl-phenyl ester;

5 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-  
4-(4-methyl-piperazin-1-ylmethyl)-phenyl ester, dihydrochloride;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[bis-(2-hydroxy-  
ethyl)-amino]-2,6-diisopropyl-phenyl ester;

10 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-  
4-(3-phenyl-thioureido)-phenyl ester; and

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-  
4-sulfamoyl-phenyl ester are excluded.

Another embodiment of the invention is a method of treating a disease or a  
disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors,  
15 comprising administering to a patient in need thereof a sulfonylaminocarbonyl  
derivative of Formula II, or a pharmaceutically acceptable salt thereof, wherein:

R<sup>1</sup> is hydrogen or alkyl of from 1 to 4 carbon atoms;

R<sup>2</sup> to R<sup>5</sup> are each alkyl of from 1 to 4 carbon atoms; and

R<sup>6</sup> is -NR<sup>7</sup>R<sup>8</sup> wherein R<sup>7</sup> and R<sup>8</sup> are each independently selected from:

20 hydrogen, at least one of R<sup>7</sup> and R<sup>8</sup> is not hydrogen,

-(CH<sub>2</sub>)<sub>1-10</sub>Z,

-C(=Q)XR<sup>11</sup>, or

-S(O)<sub>1-2</sub>R<sup>19</sup>.

Another embodiment of the invention is a method of treating a disease or a  
disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors,  
25 comprising administering to a patient in need thereof a sulfonylaminocarbonyl  
derivative of Formula II, or a pharmaceutically acceptable salt thereof, wherein:



R<sup>7</sup> is hydrogen and

R<sup>8</sup> is -C(=O)CR<sup>17</sup>R<sup>18</sup>Z wherein Z is NH<sub>2</sub> where one of R<sup>17</sup> and R<sup>18</sup> is


30 the side chain of a naturally occurring amino acid and the other is  
hydrogen.

Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative of Formula II, or a pharmaceutically acceptable salt thereof, wherein:

- 5  $R^1$  is hydrogen or alkyl of from 1 to 4 carbon atoms;  
 $R^2$  to  $R^5$  are each alkyl of from 1 to 4 carbon atoms; and  
 $R^6$  is  $NR^7R^8$ , wherein  $R^7$  and  $R^8$  taken together with the nitrogen to which they are attached to form a ring selected from:



- 10  $\text{—N—(CH}_2\text{)}_2\text{—CR}^{14}\text{R}^{15}\text{—(CH}_2\text{)}_{1-2}\text{—}$ , wherein  $R^{14}$  and  $R^{15}$  are each independently selected from hydrogen, alkyl, and phenyl; and



- 15 Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative of Formula II, or a pharmaceutically acceptable salt thereof, wherein:

- $R^1$  is hydrogen or alkyl of from 1 to 4 carbon atoms;  
20  $R^2$  to  $R^5$  are each alkyl of from 1 to 4; and  
 $R^6$  is  $NR^7R^8$ , wherein one of  $R^7$  and  $R^8$  is hydrogen and the other is  $S(O)_{1-2}R^{19}$   
wherein  $R^{19}$  is alkyl, unsubstituted or substituted phenyl, naphthyl, or a heteroaromatic ring.

Another embodiment of the invention is the method of using a compound of Formula II, or a pharmaceutically acceptable salt thereof, wherein:

- 5  $R^1$  is hydrogen or alkyl of from 1 to 4 carbons;  
 $R^2$  to  $R^5$  are alkyl of from 1 to 4 carbons; and  
 $R^6$  is  $-C(=O)XR^{11}$  or  $-CH_2R^{13}$  wherein X,  $R^{11}$ , and  $R^{13}$  are as defined above for Formula II.

10 Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative of Formula II, or a pharmaceutically acceptable salt thereof, wherein:

- $R^1$  is hydrogen or alkyl of from 1 to 4 carbon atoms;  
 $R^2$  to  $R^5$  are alkyl of from 1 to 4 carbon atoms; and  
 $R^6$  is  $-O-(CH_2)_{1-10}Z$ ,  
15  $-O-C(=O)R^{11}$ ,  
 $-SH$ ,  
 $-SCN$ ,  
 $-S(CH_2)_{1-10}Z$ , or  
 $-S(O)_{1-2}R^{12}$  wherein Z,  $R^{11}$ , and  $R^{12}$  are as defined above for  
20 Formula II.

Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative of Formula II, or a pharmaceutically acceptable salt thereof, wherein:

- 25  $R^1$  is hydrogen or alkyl of from 1 to 4 carbon atoms;  
 $R^2$  to  $R^5$  are alkyl of from 1 to 4 carbon atoms; and  
 $R^6$  is  $O(CH_2)_{1-10}NR^9R^{10}$  wherein  $R^9$  and  $R^{10}$  are as defined above for Formula II.

30 Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors,

comprising administering to a patient in need thereof a sulfonaminocarbonyl derivative of Formula II, or a pharmaceutically acceptable salt thereof, selected from:

- 5 6-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl)-hexanoic acid ethyl ester;
- 3-[3-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl)-ureido]-propionic acid ethyl ester;
- {[4-(1-Hydroxy-1-methyl-ethyl)-2,6-diisopropyl-phenyl]-acetyl}-sulfamic acid 2,6-diisopropyl-phenyl ester;
- 10 [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-4-methyl-pentanoylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoroacetic acid;
- [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-tert-butyl-ureido)-2,6-diisopropyl-phenyl ester;
- 15 [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-amino-propionylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoroacetic acid;
- [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-cyano-vinyl)-2,6-diisopropyl-phenyl ester;
- 20 [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-3-hydroxy-propionylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoroacetic acid;
- [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-4-carbamoyl-butylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoroacetic acid;
- 25 [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-3-methyl-butylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoroacetic acid;
- [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[3-(3,5-dichloro-phenyl)-thioureido]-2,6-diisopropyl-phenyl ester;
- 30 (S)-[5-tert-Butoxycarbonylamino-5-(3,5-diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenylcarbamoyl]-pentyl)-carbamic acid tert-butyl ester;

- (S)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2,6-diamino-hexanoylamino)-2,6-diisopropyl-phenyl ester dihydrochloride;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-t-butoxycarbonylamino-acetyl-amino)-2,6-diisopropyl-phenyl ester;
- 5 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-acetyl-amino)-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-t-butoxycarbonylamino-4-methylsulfanyl-butyrylamino)-2,6-diisopropyl-phenyl ester;
- 10 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-4-methylsulfanyl-butyrylamino)-2,6-diisopropyl-phenyl ester trifluoroacetate;
- 3-[3-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl)-ureido]-propionic acid ethyl ester;
- 15 3-[3-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl)-ureido]-propionic acid;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[2-amino-3-(1H-indol-3-yl)-propionylamino]-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(5-amino-pentanoylamino)-2,6-diisopropyl-phenyl ester trifluoroacetate(1:1)(salt);
- 20 (D)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-propionylamino)-2,6-diisopropyl-phenyl ester trifluoroacetate(1:1)(salt);
- (L)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-propionylamino)-2,6-diisopropyl-phenyl ester;
- 25 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-2-methyl-propionylamino)-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-dimethylamino-propoxy)-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-dimethylamino-propoxy)-2,6-diisopropyl-phenyl ester hydrochloride salt;
- 30 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-amino-propoxy)-2,6-diisopropyl-phenyl ester hydrochloride salt;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-thiocyanato-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-cyano-2,6-diisopropyl-phenyl ester;

5 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[(2-amino-acetylamino)-methyl]-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(benzylamino-methyl)-2,6-diisopropyl-phenyl ester mono hydrochloride;

10 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-carbamoyl-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-hydroxymethyl-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-acetylamino-2,6-diisopropyl-phenyl ester;

15 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-hydroxy-ethylamino)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[3-(2,6-diisopropyl-phenyl)-ureido]-2,6-diisopropyl-phenyl ester;

20 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(3-phenyl-ureido)-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(thiophene-2-sulfonylamino)-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(5-dimethylamino-naphthalene-1-sulfonylamino)-2,6-diisopropyl-phenyl ester;

25 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-methanesulfonylamino-phenyl ester;

6-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl)-hexanoic acid ethyl ester; and

30 6-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl)-hexanoic acid.

Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors,

comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative or a pharmaceutically acceptable salt thereof selected from:

(9H-Xanthene-9-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester;

5       ((E)-2-Methyl-3-phenyl-acryloyl)-sulfamic acid 2,6-diisopropyl-phenyl ester; and  
      (2-Oxo-2H-chromene-3-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester.

10       The sulfonylaminocarbonyl derivatives disclosed in United States Patent Number. 5,254,715 and its divisional 5,336,690, which are both hereby incorporated herein by reference, are also useful in the present invention. Thus, another embodiment of the present invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative selected from:

15       Carbamic acid, [(phenylamino)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

      Carbamic acid, [(phenylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-hydroxyphenyl ester;

20       Carbamic acid, [(phenylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-phenyl ester;

      Carbamic acid, [(didecylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester;

      Carbamic acid, [[bis(1-methylethyl)amino]sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

25       Carbamic acid, [(dipentylamino)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

      Carbamic acid, [[(diphenylmethyl)amino]sulfonyl]methyl-, 2,6-bis(1,1-dimethylethyl)phenyl ester;

30       DL-Tryptophan,  $\alpha$ -methyl-N-[[[(tricyclo[3.3.1.1<sup>3,7</sup>]dec-2-yloxy)carbonyl]amino]sulfonyl]-, methyl ester;

      Carbamic acid, sulfonylbis-, bis[2,6-bis(1-methylethyl)phenyl] ester;



Carbamic acid, [[[2-(phenylmethyl)phenyl]amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)phenyl ester;

Methyl[[2,6-bis(1-methylethyl)phenyl amino]sulfonyl]carbamate;

Dodecyl[[[2,6-bis(1-methylethyl)phenyl] amino]sulfonyl]carbamate;

5 2,6-Bis(1,1-dimethylethyl)-4-methoxyphenyl[[[(2,2-diphenylethyl)amino]-sulfonyl] carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methoxy phenyl [[[2,6-bis(1-methylethyl)-phenyl]amino]sulfonyl] carbamate;

10 2,6-Bis(1,1-dimethylethyl)phenyl-[[[(diphenylmethyl)amino]-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)phenyl [[[2,6-bis(1-methylethyl)phenyl]amino]-sulfonyl] carbamate;

2,6-Bis(1,1-dimethylethyl)phenyl [[[(2,2-diphenylethyl)amino]sulfonyl]-carbamate;

15 2,6-Bis(1,1-dimethylethyl)phenyl [[bis(phenylmethyl)amino]sulfonyl]-carbamate;

2,6-bis(1-methylethyl)phenyl[(diphenyl-amino)sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[(dibutyl-amino)sulfonyl]carbamate;

20 2,6-Bis(1-methylethyl)phenyl[[bis(phenyl-methyl)amino]sulfonyl]-carbamate;

2,6-Bis(1-methylethyl)phenyl[(1H-benzimidazol-2-ylamino)sulfonyl]-carbamate;

2,6-Bis(1-methylethyl)phenyl[[[(2,2-diphenylethyl)amino]sulfonyl]-carbamate;

25 2,6-Bis(1-methylethyl)phenyl[[[2,6-bis(1-methylethyl)phenyl]amino]-sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[[[(diphenyl-methyl)amino]sulfonyl]-carbamate;

30 2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[[(diphenylmethyl)amino]-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[[2,6-bis(1-methylethyl)-phenyl]amino]sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(2,2-diphenylethyl)amino]-  
sulfonyl]-carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dibutylamino)sulfonyl]-  
carbamate;

5           2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dipentylamino)sulfonyl]-  
carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[bis(1-methylethyl)amino]-  
sulfonyl]carbamate;

10           2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dihexylamino)sulfonyl]-  
carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(hexylamino)sulfonyl]-  
carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[methyl(2-phenylethyl)-  
amino]sulfonyl]carbamate;

15           2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[[bis-3-(dimethylamino)-  
propyl]amino]-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(methyl octyl amino)-  
sulfonyl]carbamate;

20           2,6-Bis(1,1-dimethylethyl)-4-methyl-[[bis[(tetrahydro-2-furanyl)methyl]-  
amino]sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dioctylamino)sulfonyl]-  
carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[[methyl 2-(2-pyridinyl)-  
ethyl]amino]sulfonyl]carbamate; hydrochloride salt,

25           2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[[methyl 2-(2-pyridinyl)-  
ethyl]amino]-sulfonyl]carbamate, sodium salt,

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dodecylamino)sulfonyl]-  
carbamate;

30           2,6-Bis(1-methylethyl)phenyl[[bis(1-methylethyl)amino]sulfonyl]-  
carbamate;

2,6-Bis(1-methylethyl)phenyl[[((1-methylethyl)phenylmethyl)amino]-  
sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[(hexyl-amino)sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[(dioctyl-amino)sulfonyl]carbamate;  
2,6-Bis(1-methylethyl)phenyl[[cyclo-hexyl(1-methylethyl)amino]-  
sulfonyl]carbamate;  
2,6-Bis(1-methylethyl)phenyl[(methyl-octylamino)sulfonyl]carbamate;  
5 2,6-Bis(1-methylethyl)phenyl[(dihexyl-amino)sulfonyl]carbamate;  
Dodecyl[[[(2,4,6-trimethoxyphenyl)amino]-sulfonyl]carbamate;  
2,6-Bis(1-methylethyl)phenyl ester(4-morpholynylsulfonyl)carbamic acid,  
2,6-Bis(1-methylethyl)phenyl ester(1-piperidinylsulfonyl)carbamic acid;  
2,6-Bis(1-methylethyl)phenyl ester(1-pyrrolidinylsulfonyl)carbamic acid;  
10 2,6-Bis(1-methylethyl)phenyl ester[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-  
carbamic acid;  
2,6-Bis(1-methylethyl)phenyl[(dibutylamino)sulfonyl]carbamate  
monosodium salt; and  
2,6-Bis(1,1-dimethylethyl)phenyl[[[(diphenylmethyl)amino]sulfonyl]-  
15 methyl carbamate.

The sulfonylaminocarbonyl derivatives disclosed in United States Patent  
Number 5,214,206 and its divisional 5,288,757, which are both hereby  
incorporated herein by reference, are also useful in the present invention. Thus,  
another embodiment of the present invention is a method of treating a disease or a  
20 disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors,  
comprising administering to a patient in need thereof a sulfonylaminocarbonyl  
derivative selected from:

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(diisopropylamino)sulfonyl]-;  
Urea, N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-N'-  
25 [[(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylmethyl)amino]sulfonyl]-, (4*S*-*cis*)-;  
Urea, N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-N'-[[[(2,2-dimethyl-4-  
phenyl-1,3-dioxan-5-yl)amino]sulfonyl]-, stereoisomer;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(1-methylethyl)amino]-  
sulfonyl]urea;  
30 N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[(diphenylmethyl)amino]-  
sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(diphenylamino)sulfonyl]urea;

- N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dibutylamino)sulfonyl]urea;  
N-[[[2,6-bis(1-methylethyl)phenyl]amino]-sulfonyl]-N'-(diphenylmethyl)-  
urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[2,6-bis(1-methylethyl)phenyl]-  
5 amino]sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[2,2-diphenylethyl]amino]-  
sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(9H-fluoren-9-ylamino)sulfonyl]-  
urea;  
10 N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(phenylmethyl)amino]sulfonyl]-  
urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[1-methylethyl](phenylmethyl)-  
amino]sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dioctylamino)sulfonyl]urea;  
15 N-[2,6-bis(1-methylethyl)phenyl]-N'-[(4-phenyl-1-piperidinyl)-  
sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dihexylamino)sulfonyl]urea;  
N-[[[bis[3-(dimethylamino)propyl]amino]-sulfonyl]-N'-[2,6-bis(1-  
methylethyl)phenyl]urea;  
20 N-[2,6-bis(1-methylethyl)phenyl]-N'-[(hexylamino)sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis-[(tetrahydro-2-  
furanyl)methyl]amino]sulfonyl]-urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(diethylamino)sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(methyloctyl amino)sulfonyl]urea;  
25 N-[2,6-bis(1-methylethyl)phenyl]-N'-[[cyclohexyl(1-methylethyl)amino]-  
sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dipentylamino)sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(2-methylpropyl)amino]-  
sulfonyl]urea;  
30 N-[2,6-bis(1-methylethyl)phenyl]-N'-[[ethyl(2-propenyl)amino]-  
sulfonyl]urea;

N-[[bis(3-methylbutyl)amino]sulfonyl]-N'-[2,6-bis(1-methylethyl)-phenyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(didecylamino)sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(didodecylamino)sulfamoyl]urea;  
5 N-[2,6-bis(1-methylethyl)phenyl]-N'-[(diisopropylamino)sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dicyclohexylamino)sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(methyloctadecylamino)-sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(di-2-propenylamino)sulfonyl]urea;  
10 N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[1;1-dimethylethyl)(1-methylethyl)amino]sulfonyl]-urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(1-methylpropyl)amino]-sulfonyl]urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(methyltetradecylamino)-sulfonyl]urea;  
15 N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-pyrrolidinylsulfonyl) urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-piperidinylsulfonyl) urea;  
N'-[[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]-N;-N-bis(phenylmethyl) urea;  
20 N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dibutylamino)sulfonyl]urea;  
monosodium salt; and  
N'-[2,6-bis(1-methylethyl)phenyl]-N-methyl-  
[(dibutylamino)sulfonyl]urea.

The sulfonylaminocarbonyl derivatives disclosed in United States Patent  
25 Number. 5,198,466 and its divisional 5,364,882, which are both hereby  
incorporated herein by reference, are also useful in the present invention. Thus,  
another embodiment of the present invention is a method of treating a disease or a  
disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors,  
comprising administering to a patient in need thereof a sulfonylaminocarbonyl  
30 derivative selected from:

Sulfamic acid, [[[[2,4,6-tris(1-methylethyl)phenyl]amino]-carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid, [[[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]-amino]carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester;  
(2,3-Dihydro-indole-1-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester;

- 5 Sulfamic acid, [[[triphenylmethyl]amino]carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester;  
Octadecyl [[[2,6-bis(1-methylethyl)phenyl]-amino]carbonyl]sulfamate;  
Dodecyl-N-[[[2,6-bis(1-methylethyl)phenyl]-amino]carbonyl]sulfamate;  
Decyl [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]sulfamate;  
10 (±) 1-Methylheptyl [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]-sulfamate;  
2,6-Bis(1-methylethyl)phenyl [[[2,6-bis(1-methylethyl)phenyl]amino]-carbonyl]sulfamate;  
(±) 1-Methylundecyl [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]-  
15 sulfamate; and  
Dodecyl [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]sulfamate, sodium salt.

The sulfonylaminocarbonyl derivatives disclosed in United States Patent Number 5,245,068 and its divisional 5,384,328, which are both hereby  
20 incorporated herein by reference, are also useful in the present invention. Thus, another embodiment of the present invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative selected from:

- 25 Carbamic acid, [(dodecyloxy)sulfonyl]-, dodecyl ester;  
Carbamic acid, [(dodecyloxy)sulfonyl]-, [1,1':3',1''-terphenyl]-2'-yl ester;  
Carbamothioic acid, [(dodecyloxy)sulfonyl]-, S-[2,6-bis(1-methylethyl)-phenyl] ester;  
Carbamic acid, (phenoxysulfonyl)-, 2,6-bis(1-methylethyl)phenyl ester;  
30 Carbamic acid, [(2,6-dimethylphenoxy)sulfonyl]-, 2,6-bis(1-methylethyl)-phenyl ester;

Carbamic acid, [[2,6-bis(1,1-dimethylethyl)phenoxy]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1,1-dimethylethyl)phenoxy]sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

5 Carbamic acid, [[2,6-difluorophenoxy]sulfonyl]-, 2,6-bis(1-methylethyl)-phenyl ester;

Carbamic acid, [(hexadecyloxy)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

10 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-dimethoxyphenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 1-methylheptyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1-methylethyl)-4-nitrophenyl ester;

15 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 1,2-ethanediyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 1,2,3-propanetriyl ester;

20 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-bromo-2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, [1,1':3',1''-terphenyl]-2'-yl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1,1dimethylethyl)-4-methoxyphenyl ester;

25 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-fluoro-2,3,5,6-tetrakis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-chloro-2,6-bis(1-methylethyl)phenyl ester;

30 Stigmasta-5,22-dien-3-ol, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-carbamate, (3 $\alpha$ )-;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester;

Stigmastan-3-ol, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]carbamate,  
(3 $\alpha$ )-;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-methoxy-  
2,6-bis(1-methylethyl)phenyl ester;

5 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4,6-tris(1-  
methylethyl)phenyl ester;

Carbamic acid, [[2,4,6-tris(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1-  
methylethyl)phenyl ester;

10 Carbamic acid, [[2,4,6-tris(1-methylethyl)phenoxy]sulfonyl]-, 2,4,6-tris(1-  
methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4,6-tris(1,1-  
dimethylethyl)phenyl ester;

15 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-[[3,5-  
bis(1,1-dimethylethyl)-4-hydroxyphenyl]dithio]-2,6-bis(1,1-dimethylethyl)phenyl  
ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4-bis(1-  
methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-,  
4-[(dimethylamino)methyl]-2,6-bis(1-methylethyl)phenyl ester;

20 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-,  
tricyclo[3.3.1.1<sup>3,7</sup>]dec-2-yl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-hydroxy-  
2,6-bis(1-methylethyl)phenyl ester;

25 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, cyclohexyl  
ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 3,3',5,5'-  
tetrakis(1-methylethyl)[1,1'-biphenyl]-4,4'-diyl ester;

Carbamic acid, [[4-hydroxy-2,6-bis(1-methylethyl)phenoxy]sulfonyl]-,  
2,6-bis(1-methylethyl)phenyl ester;

30 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-,  
tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl ester;



Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2-(1,1-dimethylethyl)-6-methylphenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 5-methyl-2-(1-methylethyl)cyclohexyl ester;

5 Carbamothioic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, *S*-[2,6-bis(1-methylethyl)phenyl] ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, (2,6-diethylphenyl)methyl ester;

10 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, (2*S*,6*S*)-2,6-bis(1-methylethyl)cyclohexyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-(1,1-dimethylethyl)-2,6-(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-fluorophenyl ester;

15 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4-difluorophenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, pentafluorophenyl ester;

20 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-difluorophenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, (2*R*,6*S*)-2,6-bis(1-methylethyl)cyclohexyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,3,5,6-tetramethylphenyl ester;

25 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 3-pyridinyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-dimethylphenyl ester;

30 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-acetyl-2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-fluoro-2,6-bis(1-methylethyl)phenyl ester;

2,6-Bis(1-methylethyl)phenyl[[2,6-bis(1-methylethyl)phenoxy]-sulfonyl]-  
carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl (phenoxysulfonyl)carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(hexyloxy)sulfonyl]carbamate;

5 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dodecyloxy-sulfonyl)-  
carbamate;

Dodecyl [[2,6-bis(1-methylethyl)phenoxy]-sulfonyl]carbamate;

Methyl[[2,6-bis(1-methylethyl)phenoxy]-sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[(hexyloxy)-sulfonyl]carbamate;

10 2,6-Bis(1-methylethyl)phenyl[(dodecyloxy)-sulfonyl]carbamate; and

2,6-Bis(1,1-dimethylethyl)phenyl[[2,6-bis(1-methylethyl)phenoxy]-  
sulfonyl]carbamate.

The sulfonylaminocarbonyl derivatives disclosed in United States Patent  
Number 5,254,589 and its continuation 5,981,595, which are both hereby  
15 incorporated herein by reference, are also useful in the present invention. Thus,  
another embodiment of the present invention is a method of treating a disease or a  
disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors,  
comprising administering to a patient in need thereof a sulfonylaminocarbonyl  
derivative selected from:

20 N-[2,6-bis(1-methylethyl)phenyl]-N'-(6-ethoxy-2-benzothiazolyl)-  
sulfonyl-urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(2-octadecylsulfonyl)urea;

N-[2,4,6-trimethoxyphenyl]-N'-(2-octadecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(tetradecylsulfonyl)urea;

25 N-[2,6-bis(1-methylethyl)phenyl]-N'-methyl-N'-(tetradecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(dodecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(hexadecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-methyl-N'-(dodecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(tridecylsulfonyl)urea;

30 N-[2,4,6-trimethoxyphenyl]-N'-(hexadecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(2-methyl-2-  
pentadecylsulfonyl)urea;

N-2,6-bis(1-methylethyl)phenyl-N'-(dodecylsulfonyl)urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-phenyl-1-tetradecylsulfonyl)urea;  
N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-phenyl-1-nonylsulfonyl)urea; and  
N-[2,6-bis(1-methylethyl)phenyl]-N'-(2-decylsulfonyl)urea.

5 The following sulfonylaminocarbonyl derivatives are excluded from use in the method of the present invention:

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dimethylamino)sulfonyl]-;

Sulfamic acid, [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]-, hexyl ester;

10 Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[[methyl(2-phenylethyl)-amino]sulfonyl]-;

Carbamic acid, [(4-methyl-1-piperazinyl)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester, monohydrochloride;

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(butylmethylamino)sulfonyl]-;

15 Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-(1-methylethyl)amino]-sulfonyl]-;

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(butylethylamino)sulfonyl]-;

Carbamic acid, [[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]-, [1,1':3',1''-terphenyl]-2'-yl ester;

20 Carbamic acid, [(2,6-dimethoxyphenoxy)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [(2,4-difluorophenoxy)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

25 Carbamic acid, [(2,4,6-trimethoxyphenoxy)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [(2,6-dimethoxyphenoxy)sulfonyl]-, 2,6-dimethoxyphenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]methyl-, 2,6-bis(1-methylethyl)phenyl ester;

30 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, ethyl ester, sodium salt;

[3-(2,4,6-Triisopropyl-phenyl)-propionyl]-sulfamic acid 2,6-diisopropyl-phenyl ester;

[Fluoro-(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester;

5 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid [1,1';3',1'']terphenyl-2'-yl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-chlorophenyl ester;

10 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, (3-pyridinyl)methyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-chloro-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(3-phenyl-thioureido)-phenyl ester;

15 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-formyl-2,6-diisopropyl-phenyl ester;

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((R)-2-amino-4-methyl-pentanoylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoroacetic acid;

20 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[bis-(2-hydroxy-ethyl)-amino]-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-sulfamoyl-phenyl ester;

25 Benzeneacetamide, N-[[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]-2,4,6-tris(1-methylethyl)-;

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(4-methyl-piperazin-1-ylmethyl)-phenyl ester; compound with generic inorganic neutral component;

30 [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-aminomethyl-2,6-diisopropyl-phenyl ester; compound with generic inorganic neutral component;

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-3-phenyl-propionylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoroacetic acid;

5 [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-3-methyl-pentanoylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoroacetic acid;

(2,3-Diphenyl-acryloyl)-sulfamic acid 3,4-dichloro-phenyl ester;

(4-Phenyl-but-3-enoyl)-sulfamic acid 2,6-diisopropyl-phenyl ester;

10 N-[2,6-bis(1-methylethyl)phenyl]-N'-phenylmethyl-N'-(tetradecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(octylsulfonyl)urea;

N-(2,4-difluorophenyl)-N'-(tetradecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(decylsulfonyl)urea;

15 N-[2,6-bis(1-methylethyl)phenyl]-N'-(2-pentadecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[6-(2,3-dihydro-1,3-dioxo-1H-isindol-2-yl)hexyl]sulfonyl]urea;

N-[[[2,6-bis(1-methylethyl)phenyl]amino]-carbonyl]-14-heptacosanesulfonylurea; and

20 N-[2,4,6-trimethoxyphenyl]-N'-(tetradecylsulfonyl)urea.

Another embodiment of the invention is a method of inhibiting NF- $\kappa$ B transcription factors in an animal, comprising administering to the animal an NF- $\kappa$ B inhibiting amount of sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof.

25 Another embodiment of the present invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is rheumatoid arthritis, osteoarthritis, an autoimmune disease, psoriasis, asthma, a cardiovascular disease, an acute  
30 coronary syndrome, congestive heart failure, Alzheimer's disease, multiple sclerosis, cancer, type 2 diabetes, metabolic syndrome X, or inflammatory bowel disease.

Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Grave's disease, myasthenia gravis, insulin resistance, autoimmune hemolytic anemia, scleroderma with anti-collagen antibodies (Abs), pernicious anemia, diabetes mellitus, psoriasis, asthma, atherosclerosis, myocardial infarction, unstable angina, congestive heart failure, Alzheimer's disease, multiple sclerosis, cancer, type 2 diabetes, metabolic syndrome X, or inflammatory bowel disease.

Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is rheumatoid arthritis.

Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is osteoarthritis.

Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is insulin resistance.

Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is asthma.

Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors,

comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is atherosclerosis.

5 Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is myocardial infarction.

10 Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is unstable angina.

15 Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is congestive heart failure.

20 Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is Alzheimer's disease.

25 Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is cancer.

30 Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is inflammatory bowel disease.

Another embodiment of the invention is a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is multiple sclerosis.

Another embodiment of the invention is a method of treating a disease or a disorder, responsive to inhibition of NF- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is type 2 diabetes.

Another embodiment of the invention is a method of treating a disease or a disorder, responsive to inhibition of NF- $\kappa$ B transcription factors, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder being treated is metabolic syndrome X.

Another embodiment of the present invention is a method for screening compounds in vitro for their ability to inhibit NF- $\kappa$ B mediated transcription of a gene, comprising analyzing an assay mixture containing stimulated NF- $\kappa$ B using fluorescence detection.

Another embodiment of the invention is a method for screening compounds in vitro for their ability to inhibit NF- $\kappa$ B mediated transcription of a gene, comprising analyzing an assay mixture containing stimulated NF- $\kappa$ B using fluorescence detection wherein the assay is a cell-based assay.

Another embodiment of the invention is a method for screening compounds in vitro for their ability to inhibit NF- $\kappa$ B mediated transcription of a gene, comprising analyzing an assay mixture containing stimulated NF- $\kappa$ B using fluorescence detection, wherein the assay is a cell-based assay and is performed in high throughput screening mode.

Another embodiment of the invention is a method for screening compounds in vitro for their ability to inhibit NF- $\kappa$ B mediated transcription of a gene, comprising analyzing an assay mixture containing stimulated NF- $\kappa$ B using fluorescence detection, the assay comprising:



Step a) Stably transfecting into cells an NF- $\kappa$ B binding site and a plasmid vector containing cDNA for an enzyme capable of cleaving a nonfluorescent substrate to produce a fluorescent cleavage product, an enzyme capable of cleaving a fluorescent substrate to produce a nonfluorescent cleavage product, or an enzyme capable of cleaving a fluorescent substrate to produce a fluorescent cleavage product;

Step b) Plating the cells of Step a) in media;

Step c) Incubating the mixture of plated cells of Step b);

Step d) Stimulating the cells of Step c) with a cytokine or a mixture of a cytokine and a compound being tested for NF- $\kappa$ B inhibition;

Step e) Adding a fluorescent disclosing reagent to the stimulated cells of Step d); and

Step f) Analyzing the mixture of Step e) by fluorescence detection.

Another embodiment of the invention is a method for screening compounds in vitro for their ability to inhibit NF- $\kappa$ B mediated transcription of a gene, comprising analyzing an assay mixture containing stimulated NF- $\kappa$ B using fluorescence detection, the assay comprising:

Step a) Stably transfecting into cells an NF- $\kappa$ B binding site and a plasmid vector containing cDNA for an enzyme capable of cleaving a nonfluorescent substrate to produce a fluorescent cleavage product, an enzyme capable of cleaving a fluorescent substrate to produce a nonfluorescent cleavage product, or an enzyme capable of cleaving a fluorescent substrate to produce a fluorescent cleavage product;

Step b) Plating the cells of Step a) in media;

Step c) Incubating the mixture of plated cells of Step b);

Step d) Stimulating the cells of Step c) with a cytokine or a mixture of a cytokine and a compound being tested for NF- $\kappa$ B inhibition;

Step e) Adding a fluorescent disclosing reagent to the stimulated cells of Step d); and

Step f) Analyzing the mixture of Step e) by fluorescence detection, wherein:

the cells undergoing transfection in Step a) are ECV-304 cells;

the cDNA being transfected in Step a) codes for  $\beta$ -lactamase;

the NF- $\kappa$ B binding site being transfected in Step a) is an HIV NF- $\kappa$ B binding site;  
the cytokine employed in Step c) is TNF- $\alpha$  or IL-1 $\beta$ ; or  
the fluorescent disclosing reagent employed in Step e) is a CCF2 dye.

5

## DETAILED DESCRIPTION OF THE INVENTION

As discussed above, the present invention provides a method of treating a disease or a disorder responsive to inhibition of nuclear factor- $\kappa$ B transcription factors comprising administering to patients in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof.

10

While as mentioned above, some of the sulfonylaminocarbonyl derivatives useful in the methods of the present invention are also inhibitors of the enzyme ACAT, and accordingly have demonstrated serum and plasma cholesterol and Lp(a) regulating activities in vivo, no connection exists between these activities and the ability of the sulfonylaminocarbonyl derivatives to inhibit NF- $\kappa$ B mediated transcription and thereby treat diseases and disorders responsive to inhibition of NF- $\kappa$ B.

15

In Formula I above, illustrative examples of straight or branched saturated hydrocarbon chains having from 1 to 20 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, n-octyl, n-undecyl, n-dodecyl, n-hexadecyl, 2,2-dimethyldodecyl, 2-tetradecyl, and n-octadecyl groups.

20

Illustrative examples of straight or branched hydrocarbon chains having from 1 to 20 carbon atoms and having from 1 to 3 double bonds include ethenyl, 2-propenyl, 2-butenyl, 3-pentenyl, 2-octenyl, 5-nonenyl, 4-undecenyl, 5-heptadecenyl, 3-octadecenyl, 9-octadecenyl, 2,2-dimethyl-11-eicosenyl, 9,12-octadecadienyl, and hexadecenyl.

25

Straight or branched alkoxy groups having from 1 to 6 carbon atoms include, for example, methoxy, ethoxy, n-propoxy, t-butoxy, and pentyloxy.

Illustrative examples of straight or branched alkyl groups having from 1 to 6 carbon atoms as used in Formula I include methyl, ethyl, n-propyl, isopropyl, n-pentyl, n-butyl, and tert-butyl.

5 Illustrative examples of cycloalkyl groups, as used in Formula I, include cyclopentyl, cyclohexyl, cyclooctyl, tetrahydronaphthyl, and 1- or 2-adamantyl.

Spirocycloalkyl groups are, for example, spirocyclopropyl, spirocyclobutyl, spirocyclopentyl, and spirocyclohexyl.

10 Illustrative examples of arylalkyl groups are: benzyl, phenethyl, 3-phenylpropyl, 2-phenylpropyl, 4-phenylbutyl, 2-phenylbutyl, 3-phenylbutyl, benzhydryl, 2,2-diphenylethyl, and 3,3-diphenylpropyl.

In Formula II above, illustrative examples of straight or branched carbon chains having from 1 to 10 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, and n-octyl.

15 Alkoxy means straight or branched groups having from 1 to 6 carbon atoms include, for example, methoxy, ethoxy, n-propoxy, t-butoxy, and pentyloxy.

20 The natural (essential) amino acids are: valine, leucine, isoleucine, threonine, methionine, phenylalanine, tryptophan, lysine, alanine, aginine, aspartic acid, cysteine, glutamic acid, glycine, histidine, proline, serine, tyrosine, asparagine, and glutamine.

Preferred natural amino acids are: valine, leucine, isoleucine, threonine, lysine, alanine, glycine, serine, asparagine, and glutamine.

25 Phenyl, naphthyl, and heteroaromatic rings are unsubstituted or substituted by from 1 to 5 substituents selected from alkyl of from 1 to 6 carbons, alkoxy, halogen, nitro, cyano, carboxylic acids and alkyl esters, amino, and hydroxyl.


Heteroaromatic rings are, for example, 2-, 3-, or 4-pyridinyl; 2-, 4-, or 5-pyrimidinyl; 2- or 3-thienyl; isoquinolines, quinolines, pyrroles, indoles, and thiazoles.

30 The phrase "sulfonylaminocarbonyl derivative" means a compound with one of the following substructure motifs:


Motif Letter

Motif Substructure


A




B



C




D




wherein Q is O or S,

E



F



10 United States Patent Number 5,254,715 and its divisional 5,336,690 describe sulfonylaminocarbonyl derivatives with substructure motif A.

United States Patent Number 5,214,206 and its divisional 5,288,757 describe sulfonylaminocarbonyl derivatives with substructure motif B.

15 United States Patent Number 5,198,466 and its divisional 5,364,882 describe sulfonylaminocarbonyl derivatives with substructure motif C.

United States Patent Number 5,245,068 and its divisional 5,384,328 describe sulfonylaminocarbonyl derivatives with substructure motif D.

United States Patent Number 5,491,172 and its divisional 5,633,287, and United States Patent Number 6,093,744 describe sulfonylaminocarbonyl derivatives with substructure motif E.

20

United States Patent Number 5,254,589 and its continuation 5,981,595 describe sulfonylaminocarbonyl derivatives with substructure motif F.

The phrase "autoimmune disease" means the diseases classified as "Highly probable" or "Probable" in TABLE 20-3. PUTATIVE AUTOIMMUNE

5 DISORDERS of The Merck Manual of Diagnosis and Therapy, 16<sup>th</sup> edition, Robert Berkow ed., Merck Research Laboratories, Rahway, New Jersey, 1992, page 340, which is hereby incorporated herein by reference. Diseases classified as highly probable include, to name a few, systemic lupus erythematosus, Grave's disease, myasthenia gravis, insulin resistance, and autoimmune hemolytic anemia.  
10 Diseases classified as probable include, to name a few, rheumatoid arthritis, scleroderma with anti-collagen antibodies (Abs), pernicious anemia, and some cases of diabetes mellitus.

Examples of a cardiovascular disease include, but are not limited to, atherosclerosis and acute coronary syndrome.

15 Examples of an acute coronary syndrome include, but are not limited to, myocardial infarction and unstable angina.

The term "patient" means a mammal, including a human, cat, dog, sheep, pig, horse, and cow.

The term "animal" means a mammal, including a human, cat, dog, sheep,  
20 cow, horse, pig, rat, mouse, guinea pig, rabbit, monkey, and transgenic variants thereof.

The phrase "NF-kB inhibiting amount" means an amount of a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof, sufficient to inhibit a NF-kB transcription factor in a particular animal or animal  
25 population. For example in a human or other mammal, an NF-kB inhibiting amount can be determined experimentally in a laboratory setting by measuring NF-kB activity in vitro according to the methods described below. Alternatively, an NF-kB inhibiting amount can be determined in vivo in an animal being treated by measuring disease-modifying affects in the conventional way. In a clinical  
30 setting, an NF-kB inhibiting amount may be determined according to the guidelines of the United States Food and Drug Administration, or equivalent

foreign agency, for the particular NF-kB transcription factor being inhibited and patient being treated.

Some of the compounds useful in the present invention may have chiral centers, in which case all stereoisomers thereof, both individual stereoisomers and mixtures of enantiomers or diastereomers, are included within the scope of the sulfonylaminocarbonyl derivatives useful in the present invention.

Some of the compounds useful in the present invention are capable of further forming nontoxic pharmaceutically acceptable acid-addition and/or base salts. All of these forms are within the scope of the compounds useful in the present invention.

For example, pharmaceutically acceptable acid addition salts of the compounds useful in the present invention include nontoxic salts derived from inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanolic acids, hydroxy alkanolic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinates suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S.M., et al., "Pharmaceutical Salts," *Journal of Pharmaceutical Science*, 1977;66:1-19).

Acid addition salts of the compounds useful in the present invention that contain a basic functional group are prepared by contacting the free base form of the sulfonylaminocarbonyl derivative with a sufficient amount of the desired acid, which amount is usually 1 molar equivalent, to produce the salt in the conventional manner.

Pharmaceutically acceptable base salts of the compounds useful in the present invention are formed with metal cations such as, for example, alkali and alkaline earth metal cations, or amines such as, for example, organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge, supra., 1977).

Base salts of the compounds useful in the present invention that contain an acidic functional group are prepared by contacting the free acid form of the sulfonylaminocarbonyl derivative with a sufficient amount of the desired base, which amount is usually 1 molar equivalent, to produce the salt in the conventional manner.

Certain of the compounds useful in the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are encompassed within the scope of the compounds useful in the present invention.

Examples of sulfonylaminocarbonyl derivatives useful in the present invention are found below. The examples are for illustration purposes, and are not to be construed as limiting the scope of the invention in any respect.

#### EXAMPLE 1

Carbamic acid, [[[diphenylmethyl)amino]sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

#### EXAMPLE 2

Carbamic acid, [[[diphenylmethyl)amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)phenyl ester

#### EXAMPLE 3

Carbamic acid, [[[diphenylmethyl)amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

EXAMPLE 4

Carbamic acid, [[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 5

5 Carbamic acid, [[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)phenyl ester

EXAMPLE 6

Carbamic acid, [[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

EXAMPLE 7

10 Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[2,6-bis(1-methylethyl)phenyl]-amino]sulfonyl]-

EXAMPLE 8

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[(diphenylmethyl)amino]-sulfonyl]-

EXAMPLE 9

15 Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[(2,2-diphenylethyl)amino]-sulfonyl]-

EXAMPLE 10

Carbamic acid, [[[2,2-diphenylethyl)amino]sulfonyl]-, 2,6-bis(1-methylethyl)-phenyl ester

EXAMPLE 11

20 Carbamic acid, [[[2,2-diphenylethyl)amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-phenyl ester

EXAMPLE 12

25 Carbamic acid, [[[2,2-diphenylethyl)amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester



EXAMPLE 13

Carbamic acid, [(phenylamino)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 14

5 Carbamic acid, [(phenylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-hydroxyphenyl ester

EXAMPLE 15

Carbamic acid, [(phenylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-phenyl ester

EXAMPLE 16

10 Carbamic acid, [(1H-benzimidazol-2-ylamino)sulfonyl]-, 2,6-bis(1-methylethyl)-phenyl ester

EXAMPLE 17

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(phenylmethyl)amino]-sulfonyl]-urea

EXAMPLE 18

N-[[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]-N'-(diphenylmethyl)-urea

15 EXAMPLE 19

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(9H-fluoren-9-ylamino)-sulfonyl]-urea

EXAMPLE 20

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(1-methylethyl)amino]-sulfonyl]-urea

EXAMPLE 21

20 N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dibutylamino)sulfonyl]-urea

EXAMPLE 22

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[(1-methylethyl)-(phenylmethyl)amino]-sulfonyl]-urea

EXAMPLE 23

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dioctylamino)sulfonyl]-urea

EXAMPLE 24

5 Carbamic acid, [[bis(phenylmethyl)amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-phenyl ester

EXAMPLE 25

Carbamic acid, [[bis(phenylmethyl)amino]sulfonyl]-, 2,6-bis(1-methylethyl)-phenyl ester

EXAMPLE 26

10 Carbamic acid, [(diphenylamino)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 27

Carbamic acid, [(dibutylamino)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 28

15 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 29

N'-[[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]-N,N-bis(phenylmethyl)-urea

EXAMPLE 30

20 Carbamic acid, [(dibutylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

EXAMPLE 31

Carbamic acid, [(dipentylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

EXAMPLE 32

Carbamic acid, [[bis(1-methylethyl)amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

EXAMPLE 33

- 5 Carbamic acid, [(dihexylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

EXAMPLE 34

Carbamic acid, [(hexylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

EXAMPLE 35

- 10 N-[2,6-bis(1-methylethyl)phenyl]-N'-[(4-phenyl-1-piperidiny)-sulfonyl]-urea

EXAMPLE 36

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dihexylamino)sulfonyl]-urea

EXAMPLE 37

- 15 N-[[bis[3-(dimethylamino)propyl]amino]sulfonyl]-N'-[2,6-bis(1-methylethyl)phenyl]-urea

EXAMPLE 38

Carbamic acid, [[methyl(2-phenylethyl)amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

20

EXAMPLE 39

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(hexylamino)sulfonyl]-urea

EXAMPLE 40

Carbamic acid, [[bis[3-(dimethylamino)propyl]amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

EXAMPLE 41

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]-urea,

EXAMPLE 42

- 5 Carbamic acid, [[methyl[2-(2-pyridinyl)ethyl]amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester, monohydrochloride

EXAMPLE 43

Carbamic acid, [(methyloctylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

EXAMPLE 44

- 10 Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(diethylamino)sulfonyl]-

EXAMPLE 45

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(methyloctylamino)sulfonyl]-

EXAMPLE 46

- 15 Carbamic acid, [(dioctylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

EXAMPLE 47

Carbamic acid, [[(2,2-diphenylethyl)amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methoxyphenyl ester

EXAMPLE 48

- 20 Carbamic acid, (phenoxysulfonyl)-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

EXAMPLE 49

- 25 Carbamic acid, [(hexyloxy)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

EXAMPLE 50

Carbamic acid, [[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methoxyphenyl ester

EXAMPLE 51

- 5 Carbamic acid, [(dodecyloxy)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

EXAMPLE 52

Carbamic acid, [(didecylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

10

EXAMPLE 53

Carbamic acid, [[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]-, dodecyl ester

EXAMPLE 54

Carbamic acid, [[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]-, methyl ester

EXAMPLE 55

- 15 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, dodecyl ester

EXAMPLE 56

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, methyl ester

EXAMPLE 57

Carbamic acid, [(hexyloxy)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

20

EXAMPLE 58

Carbamic acid, (4-morpholinylsulfonyl)-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 59

Carbamic acid, (1-piperidinylsulfonyl)-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 60

Sulfamic acid, [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]-, octadecyl ester

EXAMPLE 61

Carbamic acid, [(dodecyloxy)sulfonyl]-, dodecyl ester

5

EXAMPLE 62

Carbamic acid, [[bis(1-methylethyl)amino]sulfonyl]-, 2,6-bis(1-methylethyl)-phenyl ester

EXAMPLE 63

10

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[[cyclohexyl(1-methylethyl)amino]sulfonyl]-

EXAMPLE 64

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dipentylamino)sulfonyl]-

EXAMPLE 65

15

Carbamic acid, [(((1-methylethyl)phenylmethyl)amino)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 66

Carbamic acid, (1-pyrrolidinylsulfonyl)-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 67

Carbamic acid, [(hexylamino)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

20

EXAMPLE 68

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(2-methylpropyl)amino]sulfonyl]-

EXAMPLE 69

Sulfamic acid, [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]-, dodecyl ester

EXAMPLE 70

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-pyrrolidinylsulfonyl)-

EXAMPLE 71

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-piperidinylsulfonyl)-

5

EXAMPLE 72

Carbamic acid, [(2,3-dihydro-1H-indol-1-yl)sulfonyl]-, 2,6-bis(1-methylethyl)-phenyl ester

EXAMPLE 73

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[[ethyl(2-propenyl)amino]-sulfonyl]-

10

EXAMPLE 74

Urea, N-[[bis(3-methylbutyl)amino]sulfonyl]-N'-[2,6-bis(1-methylethyl) phenyl]-

EXAMPLE 75

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(didecylamino)sulfonyl]-

EXAMPLE 76

15 Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(didodecylamino)sulfonyl]-

EXAMPLE 77

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dipropylamino)sulfonyl]-

EXAMPLE 78

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dicyclohexylamino)-sulfonyl]-

20

EXAMPLE 79

Carbamic acid, [(2,4,6-trimethoxyphenyl)amino]sulfonyl]-, dodecyl ester

EXAMPLE 80

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(methyloctadecylamino)-sulfonyl]-

EXAMPLE 81

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(di-2-propenylamino)-sulfonyl]-

EXAMPLE 82

5 Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[(1,1-dimethylethyl)(1-methylethyl)-amino]sulfonyl]-

EXAMPLE 83

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(1-methylpropyl)-amino]-sulfonyl]-

EXAMPLE 84

10 Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(methyltetradecylamino)-sulfonyl]-

EXAMPLE 85

Carbamic acid, [(dioctylamino)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 86

15 Carbamic acid, [[cyclohexyl(1-methylethyl)amino]sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 87

Carbamic acid, [(methyloctylamino)sulfonyl]-, 2,6-bis(1-methylethyl)-phenyl ester

EXAMPLE 88

20 Carbamic acid, [(dihexylamino)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 89

Carbamic acid, [(dipentylamino)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 90

Sulfamic acid, [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]-, decyl ester



EXAMPLE 91

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)phenyl ester

EXAMPLE 92

5 Carbamic acid, [(dodecyloxy)sulfonyl]-, [1,1':3',1''-terphenyl]-2'-yl ester

EXAMPLE 93

Carbamothioic acid, [(dodecyloxy)sulfonyl]-, S-[2,6-bis(1-methylethyl)-phenyl] ester

EXAMPLE 94

10 Sulfamic acid, [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]-, 1-methylheptyl ester,

EXAMPLE 95

Sulfamic acid, [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester

15

EXAMPLE 96

Carbamic acid, [[[diphenylmethyl]amino]sulfonyl]methyl-, 2,6-bis(1,1-dimethylethyl)phenyl ester

EXAMPLE 97

Carbamic acid, (phenoxy)sulfonyl-, 2,6-bis(1-methylethyl)phenyl ester

20

EXAMPLE 98

Carbamic acid, [(2,6-dimethylphenoxy)sulfonyl]-, 2,6-bis(1-methylethyl)-phenyl ester

EXAMPLE 99

Urea, N'-[2,6-bis(1-methylethyl)phenyl]-N-[(dibutylamino)sulfonyl]-N-methyl-

EXAMPLE 100

Carbamic acid, [[2,6-bis(1,1-dimethylethyl)phenoxy]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)phenyl ester

EXAMPLE 101

- 5 DL-Tryptophan,  $\alpha$ -methyl-N-[[[(tricyclo[3.3.1.1<sup>3,7</sup>]dec-2-yloxy)-carbonyl]amino]sulfonyl]-, methyl ester

EXAMPLE 102

Carbamic acid, [[2,6-bis(1,1-dimethylethyl)phenoxy]sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

- 10 EXAMPLE 103

Carbamic acid, [(2,6-difluorophenoxy)sulfonyl]-, 2,6-bis(1-methylethyl)-phenyl ester

EXAMPLE 104

- 15 Urea, N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-N'-[[[(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylmethyl)amino]sulfonyl]-, (4S-#cis/-

EXAMPLE 105

Urea, N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-N'-[[[(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)amino]sulfonyl]-, stereoisomer

EXAMPLE 106

- 20 Sulfamic acid, (1-oxodecyl)-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 107

Carbamic acid, [(hexadecyloxy)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 108

- 25 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-dimethoxyphenyl ester

EXAMPLE 109

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 1-methylheptyl ester

EXAMPLE 110

5 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1-methylethyl)-4-nitrophenyl ester

EXAMPLE 111

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 1,2-ethanediyl ester

EXAMPLE 112

10 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 1,2,3-propanetriyl ester

EXAMPLE 113

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-bromo-2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 114

15 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, [1,1':3',1''-terphenyl]-2'-yl ester

EXAMPLE 115

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methoxyphenyl ester

20

EXAMPLE 116

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-fluoro-2,3,5,6-tetrakis(1-methylethyl)phenyl ester

EXAMPLE 117

25 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-chloro-2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 118

Stigmasta-5,22-dien-3-ol, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-carbamate, (3 $\alpha$ )-

EXAMPLE 119

5 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester

EXAMPLE 120

Sulfamic acid, [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 121

10 Stigmastan-3-ol, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-carbamate, (3 $\alpha$ )-

EXAMPLE 122

Sulfamic acid, [[2,6-bis(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)-phenyl ester

EXAMPLE 123

15 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-methoxy-2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 124

20 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4,6-tris(1-methylethyl)phenyl ester

EXAMPLE 125

Carbamic acid, [[2,4,6-tris(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 126

Carbamic acid, [[2,4,6-tris(1-methylethyl)phenoxy]sulfonyl]-,2,4,6-tris(1-methylethyl)phenyl ester

EXAMPLE 127

- 5 Carbamic acid, [[2,4,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4,6-tris(1,1-dimethylethyl)phenyl ester

EXAMPLE 128

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]dithio]-2,6-bis(1,1-dimethylethyl)phenyl ester

10

EXAMPLE 129

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4-bis(1-methylethyl)phenyl ester

EXAMPLE 130

15

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-[(dimethylamino)-methyl]-2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 131

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, tricyclo[3.3.1.1<sup>3,7</sup>]-dec-2-yl ester

EXAMPLE 132

20

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-hydroxy-2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 133

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, cyclohexyl ester

EXAMPLE 134

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 3,3',5,5'-tetrakis(1-methylethyl)[1,1'-biphenyl]-4,4'-diyl ester

EXAMPLE 135

- 5 Carbamic acid, [[4-hydroxy-2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 136

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, tricyclo[3.3.1.<sup>3,7</sup>]-dec-1-yl ester

- 10 EXAMPLE 137

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2-(1,1-dimethylethyl)-6-methylphenyl ester

EXAMPLE 138

- 15 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 5-methyl-2-(1-methylethyl)cyclohexyl ester

EXAMPLE 139

Carbamothioic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, S-[2,6-bis(1-methylethyl)phenyl] ester

EXAMPLE 140

- 20 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, (2,6-diethylphenyl)methyl ester

EXAMPLE 141

Carbamic acid, sulfonylbis-, bis[2,6-bis(1-methylethyl)phenyl] ester

EXAMPLE 142

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, (2*S*,6*S*)-2,6-bis(1-methylethyl)cyclohexyl ester

EXAMPLE 143

- 5 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-(1,1-dimethylethyl)-2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 144

(2-Phenyl-cyclopropanecarbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 145

- 10 [(2,5-Dimethoxy-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 146

[(2,4,6-Trimethyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 147

[(2,4,6-Trimethoxy-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester

- 15 EXAMPLE 148

(Thiophen-2-yl-acetyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 149

(Thiophen-3-yl-acetyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 150

- 20 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-fluorophenyl ester

EXAMPLE 151

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4-difluorophenyl ester

EXAMPLE 152

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, pentafluorophenyl ester

EXAMPLE 153

5 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-difluorophenyl ester

EXAMPLE 154

Acetic acid 2-(2,6-diisopropyl-phenoxy-sulfonylamino)-2-oxo-1-(2,4,6-triisopropyl-phenyl)-ethyl ester

EXAMPLE 155

10 Cyclohexylacetyl-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 156

[(2-Methoxy-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 157

15 (Oxo-phenyl-acetyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 158

[(2-Trifluoromethyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 159

(2-Phenyl-propionyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 160

20 Diphenylacetyl-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 161

(Cyclopentyl-phenyl-acetyl)-sulfamic acid 2,6-diisopropyl-phenyl ester



EXAMPLE 162

[Hydroxy-(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 163

5 Triphenylacetyl-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 164

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, (2*R*,6*S*)-2,6-bis(1-methylethyl)cyclohexyl ester

EXAMPLE 165

10 (1,2,3,4-Tetrahydro-naphthalene-2-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 166

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,3,5,6-tetramethylphenyl ester

15

EXAMPLE 167

(3-Methyl-2-phenyl-pentanoyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 168

(1-Phenyl-cyclopentanecarbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 169

20 (2-Phenyl-butyryl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 170

(Cyclohexyl-phenyl-acetyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 171

(2,2-Diphenyl-propionyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 172

[Bis-(4-chloro-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 173

(9H-Xanthene-9-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

5

EXAMPLE 174

(9H-Fluorene-9-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 175

(Bromo-phenyl-acetyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 176

10 (3-Phenyl-propionyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 177

Sulfamic acid, [[[2,4,6-tris(1-methylethyl)phenyl]amino]carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 178

15 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 3-pyridinyl ester

EXAMPLE 179

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-dimethylphenyl ester

EXAMPLE 180

20 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-hydroxy-2,6-diisopropyl-phenyl ester

EXAMPLE 181

Methyl-[(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 182

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-nitro-phenyl ester

EXAMPLE 183

5 Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-acetyl-2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 184

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-fluoro-2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 185

10 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-fluoro-2,6-diisopropyl-phenyl ester

EXAMPLE 186

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-dimethoxy-phenyl ester

EXAMPLE 187

15 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-amino-2,6-diisopropyl-phenyl ester

EXAMPLE 188

20 6-(3,5-Diisopropyl-4-[[[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy]-phenyl]-hexanoic acid ethyl ester

EXAMPLE 189

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,4,6-trimethoxy-phenyl ester

EXAMPLE 190

25 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-tert-butyl-2,6-diisopropyl-phenyl ester

EXAMPLE 191

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-acetyl-2-isopropyl-phenyl ester

EXAMPLE 192

5 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-methoxy-phenyl ester

EXAMPLE 193

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-dichloro-phenyl ester

EXAMPLE 194

10 3-[3-(3,5-Diisopropyl-4- {[(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamoyloxy}-phenyl)-ureido]-propionic acid ethyl ester

EXAMPLE 195

[5-tert-Butoxycarbonylamino-5-(3,5-diisopropyl-4- {[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy}-phenylcarbamoyl)-pentyl]-carbamic acid tert-butyl ester

15

EXAMPLE 196

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-acetylamino-2,6-diisopropyl-phenyl ester

EXAMPLE 197

20 [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2,6-diamino-hexanoylamino)-2,6-diisopropyl-phenyl ester; compound with generic inorganic neutral component

EXAMPLE 198

[(3,5-Diisopropyl-4- {[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy}-phenylcarbamoyl)-methyl]-carbamic acid tert-butyl ester

25

EXAMPLE 199

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid dodecyl ester

EXAMPLE 200

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-acetyl-amino)-2,6-diisopropyl-phenyl ester

EXAMPLE 201

5 [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-4-methylsulfanyl-butyl-amino)-2,6-diisopropyl-phenyl ester

EXAMPLE 202

{[4-(1-Hydroxy-1-methyl-ethyl)-2,6-diisopropyl-phenyl]-acetyl}-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 203

10 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-bromo-2,6-diisopropyl-phenyl ester

EXAMPLE 204

15 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[2-amino-3-(1H-indol-3-yl)-propionyl-amino]-2,6-diisopropyl-phenyl ester

EXAMPLE 205

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-dimethyl-amino-propoxy)-2,6-diisopropyl-phenyl ester

EXAMPLE 206

20 [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((R)-2-amino-propionyl-amino)-2,6-diisopropyl-phenyl ester; compound with trifluoro-acetic acid

EXAMPLE 207

25 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-2-methyl-propionyl-amino)-2,6-diisopropyl-phenyl ester

EXAMPLE 208

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-amino-propoxy)-2,6-diisopropyl-phenyl ester

EXAMPLE 209

5 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-thiocyanato-phenyl ester

EXAMPLE 210

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-methyl-phenyl ester

EXAMPLE 211

10 [1-(4-Dimethylamino-phenyl)-cyclopentanecarbonyl]-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 212

15 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-cyano-2,6-diisopropyl-phenyl ester

EXAMPLE 213

[1-(4-Nitro-phenyl)-cyclopentanecarbonyl]-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 214

20 [1-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenylcarbamoyl]-3-methylsulfanyl-propyl]-carbamic acid tert-butyl ester

EXAMPLE 215

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[3-(2,6-diisopropyl-phenyl)-ureido]-2,6-diisopropyl-phenyl ester

EXAMPLE 216

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-4-methyl-pentanoylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoro-acetic acid

5

EXAMPLE 217

Sulfamic acid, [[[[1-[4-(dimethylamino)phenyl]cyclopentylmethyl]-amino]carbonyl]- 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 218

10

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(3-phenyl-ureido)-phenyl ester

EXAMPLE 219

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-tert-butyl-ureido)-2,6-diisopropyl-phenyl ester

EXAMPLE 220

15

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-amino-propionylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoro-acetic acid

EXAMPLE 221

Carbamic acid, [[[[2-(phenylmethyl)phenyl]amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)phenyl ester

20

EXAMPLE 222

(2,3-Dihydro-indole-1-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 223

Sulfamic acid, [[(triphenylmethyl)amino]carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester

EXAMPLE 224

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-cyano-vinyl)-2,6-diisopropyl-phenyl ester

EXAMPLE 225

5 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(thiophene-2-sulfonylamino)-phenyl ester

EXAMPLE 226

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(5-dimethylamino-naphthalene-1-sulfonylamino)-2,6-diisopropyl-phenyl ester

10 EXAMPLE 227

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-methanesulfonylamino-phenyl ester

EXAMPLE 228

15 3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy}-benzoic acid methyl ester

EXAMPLE 229

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(benzylamino-methyl)-2,6-diisopropyl-phenyl ester; compound with generic inorganic neutral component

EXAMPLE 230

20 [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-3-hydroxy-propionylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoro-acetic acid

EXAMPLE 231

25 [2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-4-carbamoyl-butyrylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoro-acetic acid



EXAMPLE 232

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-3-methyl-butrylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoro-acetic acid

EXAMPLE 233

- 5 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-hydroxymethyl-2,6-diisopropyl-phenyl ester

EXAMPLE 234

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-carbamoyl-2,6-diisopropyl-phenyl ester

- 10 EXAMPLE 235

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[3-(3,5-dichloro-phenyl)-thioureido]-2,6-diisopropyl-phenyl ester

EXAMPLE 236

((E)-2-Methyl-3-phenyl-acryloyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

- 15 EXAMPLE 237

(2-Oxo-2H-chromene-3-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester

EXAMPLE 238

N-[2,6-bis(1-methylethyl)phenyl]-N'-(hexadecylsulfonyl)-urea

EXAMPLE 239

- 20 N-[2,6-bis(1-methylethyl)phenyl]-N'-[(6-ethoxy-2-benzothiazolyl)sulfonyl]-urea

EXAMPLE 240

N-[2,6-bis(1-methylethyl)phenyl]-N'-(tetradecylsulfonyl)-urea

EXAMPLE 241

N'-[2,6-bis(1-methylethyl)phenyl]-N-methyl-N-(tetradecylsulfonyl)-urea

EXAMPLE 242

N-[2,6-bis(1-methylethyl)phenyl]-N'-(tridecylsulfonyl)urea

EXAMPLE 243

N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-phenyl-1-nonylsulfonyl)urea

5

EXAMPLE 244

N-[2,6-bis(1-methylethyl)phenyl]-N'-(2-decylsulfonyl)urea

EXAMPLE 245

N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-phenyl-1-tetradecylsulfonyl)urea

EXAMPLE 246

10 N-[2,6-bis(1-methylethyl)phenyl]-N'-(2-octadecylsulfonyl)urea

EXAMPLE 247

N-[2,4,6-trimethoxyphenyl]-N'-(2-octadecylsulfonyl)urea

EXAMPLE 248

N-[2,6-bis(1-methylethyl)phenyl]-N'-(2-methyl-2-pentadecylsulfonyl)urea

15

EXAMPLE 249

N-[2,4,6-trimethoxyphenyl]-N'-(2-methyl-2-pentadecylsulfonyl)urea

EXAMPLE 250

Carbamic acid, [[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]-, dodecyl ester

20

Sulfonylaminocarbonyl derivatives useful in the present invention may be identified using the methods described below.

## BIOLOGICAL METHODS

Introduction: Described below is an in vitro, cell-based, high throughput screening assay that reliably identifies inhibitors of NF- $\kappa$ B mediated transcription. While the assay described below utilized inhibitors which were  
5 sulfonylaminocarbonyl derivatives useful in the present invention, the assay may be used to screen for any inhibitor of NF- $\kappa$ B mediated transcription.

The assay takes advantage of AURORA (Aurora Bioscience Corporation, La Jolla, California) fluorescence technology. Endothelial cell vein-304 (ECV-304) cells, an endothelial-like immortalized cell type, may be stably  
10 transfected with a plasmid vector containing the cDNA for the enzyme  $\beta$ -lactamase (under the control of a basal promoter, Stratagene pNF $\kappa$ B-luc vector) and 5 copies of an human immunodeficiency virus-1 (HIV-1) NF- $\kappa$ B binding site. ECV-304 cells are described by Takahashi K. et al. in Spontaneous  
15 Transformation and Immobilization of Human Endothelial Cells, *In Vitro Cell Dev. Biol.* 1990;25:265-274. Activation of NF- $\kappa$ B in ECV-304 by cytokines such as TNF- $\alpha$  or interleukin-1 beta (IL-1 $\beta$ ) results in the production of  $\beta$ -lactamase, which cleaves a green fluorescent substrate (excitation/emission wavelengths  
395 nm/530 nm) to yield a blue fluorescent product (excitation/emission wavelengths 395 nm/460 nm). Visually, the uncleaved green fluorescent substrate  
20 is sequestered intracellularly and emits green fluorescence, while the cleaved product emits blue fluorescence. Fluorescence is quantitated spectrophotometrically, and the spectral intensity of blue fluorescence versus green fluorescence can be used to calculate the degree of activation of NF- $\kappa$ B.

The assay was performed as outlined here and described in detail below.  
25 ECV-304 cells permanently transfected with the NF- $\kappa$ B driven  $\beta$ -lactamase gene (ECV-304 NF- $\kappa$ B. $\beta$ laZ) were plated in clear-bottom, black 96-well plates ( $1.25 \times 10^4$  cells/well) in media-199 (M-199) media containing 2% fetal bovine serum (FBS). Approximately 18 hours later the cells were stimulated with either  
30 10 ng/mL of TNF- $\alpha$  or 100 pg/mL of IL-1 $\beta$ , and incubated for 6 hours at 37°C in the presence or absence of a compound useful in the present invention. The AURORA fluorescent disclosing reagent was then added. After one additional

hour, the plates were read in a fluorometer at the blue 395 nm/460 nm (excitation/emission) and green 395 nm/530 nm wavelengths. Then the blue/green emission ratio was calculated. Percent inhibition was calculated by comparing fluorescence in the presence of a sulfonylaminocarbonyl derivative useful in the present invention with fluorescence in the absence of said sulfonylaminocarbonyl derivative under conditions of maximum stimulation with TNF- $\alpha$  or IL-1 $\beta$ . An IC<sub>50</sub> for said sulfonylaminocarbonyl derivative was determined from a dose-response curve. This assay was designed to be optionally run in either high or low throughput screening modes.

Materials: ECV-304 cells were obtained from American Type Culture Collection (ATCC). Cytokines TNF- $\alpha$  and IL-1 $\beta$  were obtained from R&D Systems. Lipofectamine, M199, and penicillin/streptomycin 1000 U (P/S) were from GIBCO-BRL. Reagents A, B, and C are proprietary reagents from Aurora Technologies. The FBS is from Summit Technologies. The CCF2 dye was from Aurora Biosciences, La Jolla, California.


Methods:

(i) ECV-304 NF- $\kappa$ B.  $\beta$ laZ Cell Line:

Five copies of the HIV-1 NF- $\kappa$ B binding site (5'-TGGGGACTTTCCGC-3') along with a TATA box were inserted into the EcorRI/BamHI sites of plasmid pMCRBlaZ to create plasmid p5xKBBlaz, which procedure is illustrated in Scheme 1 below.

Scheme 1

Five copies of the HIV-1 NF- $\kappa$ B binding site  
+ TATA box  
+ plasmid pMCRBlaZ  $\longrightarrow$



Plasmid p5xKBBlaz

The parental plasmid, pMCRBlaZ, contains a multiple cloning site upstream of the  $\beta$ -lactamase gene as well as a Zeocin antibiotic resistance gene.

Plasmid p5xKBBlaZ was transfected into ECV-304 cells using lipofectamine and the well-known standard conditions found on the package insert. Cells were selected for antibiotic resistance with Zeocin for approximately 2 weeks. After the stable population had been expanded to a significant number of cells, it was stimulated with IL-1 $\beta$  and stained with AURORA CCF2 dye, a membrane permeant, intracellularly-trapped, fluorescent substrate. Cells that fluoresced blue (indicating a positive response of the NF- $\kappa$ B/ $\beta$ -lactamase reporter to stimulation by IL-1 $\beta$ ) in the stimulated/stained population were then sorted by flow cytometry into a pool. The pool was expanded and stained with CCF2, and then the cells that fluoresced green from this unstimulated population (indicating a low background of the NF- $\kappa$ B/ $\beta$ -lactamase reporter construct) were cloned by flow cytometry after adding 1 cell per well in 96-well plates. Clones were allowed to expand. Each cloned cell line was then examined for fold stimulation after stimulation with IL-1 $\beta$  using a CCF2 reporter assay, and these stimulated cells were compared to unstimulated cells. The cloned cell line with the maximal fold induction (plate 1, row E, cell 8 or 1E8) was chosen for further assay development. This clone consistently showed the highest fluorescence signal to noise ratio upon stimulation with TNF- $\alpha$  or IL-1 $\beta$ .

(ii) Assay Development: The assay described herein was initially developed for high throughput screening purposes. As such, several factors were taken into consideration in the process. The assay was developed to minimize handling (i.e., no media changes, washes, etc.). Conditions were established to optimize the incubation period to 4 to 6 hours for logistical reasons. The assay was also optimized to its ability to tolerate the presence or absence of serum and the concentration of dimethylsulfoxide (DMSO) that could be used without interference of the fluorescence generated from the activation of NF- $\kappa$ B. Cytokine stability and optimal cell density were also optimized. Also, no difference in NF- $\kappa$ B stimulation in ECV-304 cells separated in lineage by 20 passages (Passages 5 and 25) was found.

(iii) Reagents:

Cells: ECV-304 NF- $\kappa$ B  $\beta$ -Lactamase clone 1E8

Complete Media: M199, 10%FBS (nonheat inactivated), 1% P/S,  
200 µg/mL Zeocin;

Assay Media: M199, 2% FBS, no antibiotics

Cell Culture:  $0.5 \times 10^6$  cells/T 150 culture flask, 30 mL complete media,  
5 fed every other day; harvested Day 7, approximate yield 1.1 (107/flask)

Assay Seeding Density:  $1.78 \times 10^5$ /mL, 70 µL/well-96-well plate,  
(12,500 cells/well)

Quality Controls: The proteasome inhibitors MG132, MG262, and clasto-  
lactacystine  $\beta$ -lactone may be used, as these agents irreversibly inhibit the  
10 proteasomal breakdown of I $\kappa$ B (McCormick et al., *Journal of Biological Chemistry*, 1997;272(42):26103-26109 and Craai et al., *Journal of Biological Chemistry*, 1997;272(20):13437-13445.)

Inhibitors: Prepared stock solutions of aminosulfonyl derivatives at 10 mM  
concentration in DMSO;

15 Diluted stock solutions in 96-well diluting plate as follows:

a) Added 20 µL of stock solution into 180 µL of M199 = A,

b) Added 20 µL A into 180 µL M199 = B,

c) Added 10 µL of B into appropriate well in assay plate (the final  
concentration of drug is 10 µM), and

20 (d) Diluted further for IC<sub>50</sub> determinations.

Activation Cytokines TNF- $\alpha$  and IL-1 $\beta$ :

Stock solution of TNF- $\alpha$ : R&D Systems 210-TA, 10 µg was diluted into  
2 mL of phosphate buffered saline (PBS) containing 0.1% bovine serum albumin  
(BSA) (concentration of TNF- $\alpha$  = 5 µg/mL);

25 Diluted TNF- $\alpha$  stock solution 1:100: 90 µL of TNF- $\alpha$  stock solution was  
diluted into 9.0 mL of M199 media (concentration of TNF- $\alpha$  = 50 ng/mL); and

Added 20 µL of the solution of TNF- $\alpha$  at 50 ng/mL to all wells except  
reagent control wells, and cell control wells (final concentration of TNF- $\alpha$  in  
well = 10 ng/mL).

30 Stock solution of IL-1 $\beta$ : R&D Systems 203-LB, 5 µg was diluted into  
1 mL of PBS containing 0.1% BSA (concentration of IL-1 $\beta$  = 5 µg/mL);

Diluted the IL-1 $\beta$  stock solution 1:1000: 20  $\mu$ L of IL-1 $\beta$  stock solution was diluted into 20 mL of M199 (concentration of IL-1 $\beta$  = 5 ng/mL);

Diluted the 5 ng/mL solution of IL-1 $\beta$  1:10: 0.5 mL of the 5 ng/mL solution IL-1 $\beta$  at a concentration of 5 ng/mL was diluted into 5.0 mL of M199 (concentration of IL-1 $\beta$  = 500 pg/mL); and

Added 20  $\mu$ L the solution of the 500 pg/mL IL-1 $\beta$  at to all wells except reagent control wells and cell control wells (final concentration IL-1 $\beta$  in well = 100 pg/mL).

(iv) A High Throughput Screening Assay Procedure:

Table 1. Plate Map

	1	2	3	4	5	6	7	8	9	10	11	12
<b>A</b>	USC	T	O	O	O	O	O	O	O	O	O	B
<b>B</b>	USC	T	O	O	O	O	O	O	O	O	O	B
<b>C</b>	USC	T	O	O	O	O	O	O	O	O	O	B
<b>D</b>	USC	T	O	O	O	O	O	O	O	O	O	B
<b>E</b>	USC	T	O	O	O	O	O	O	O	O	O	B
<b>F</b>	USC	T	O	O	O	O	O	O	O	O	O	B
<b>G</b>	USC	MG	O	O	O	O	O	O	O	O	O	B
<b>H</b>	USC	MG	O	O	O	O	O	O	O	O	O	B

Column 1 = **USC**, Unstimulated cell control wells.

Column 2 A-F = **T**, Maximal activation control wells.

Column 2 G-H = **MG**, MG132 quality control.

Column 12 = **B**, Reagent background wells.

Columns 3-11 = **O**, Sulfonylaminocarbonyl derivatives in triplicate at a concentration of 10  $\mu$ M (for screening purposes) or at varying concentrations for dose response studies (IC<sub>50</sub>).

10

Plates for the HTS are configured in an alternative format.

PM Day 1: Seeded cells at  $0.178 \times 10^6$ /mL, 70  $\mu$ L/well, in assay media



AM Day 2:

a) DMSO Control: Added 10  $\mu\text{L}$  of a 1% DMSO solution in M199 to the following wells (final concentration of DMSO in well = 0.1%): Added to B wells (reagent control: assay media, no cytokine, no cells), USC wells (unstimulated cell control: cells, assay media, no activation cytokine), and T wells (maximal activity: cells, assay media, cytokine);

b) Inhibitor: Added 10  $\mu\text{L}$  of a sulfonylaminocarbonyl derivative at 10 $\times$  desired final concentration to the following wells: Added to all O wells (unknowns: cells, assay media, cytokine) and MG wells (quality control: cells, assay media, cytokine). No inhibitor should be added to USC wells, B wells, or T wells.

c) Activation Cytokine: Added 20  $\mu\text{L}$  of the 50 ng/mL solution of TNF- $\alpha$  (to give a 10 ng/mL final concentration of TNF- $\alpha$ ) or 20  $\mu\text{L}$  of the 500 pg/mL solution of IL-1 $\beta$  (to give a 100 pg/mL final concentration of IL-1 $\beta$ ) to all T wells, O wells, and MG wells. No cytokine was added to USC wells or B wells.

d) Incubation after stimulation of cells with an activation cytokine, with or without a sulfonylaminocarbonyl derivative: 6 hours, 37°C, 5% CO<sub>2</sub> atmosphere

e) Preparation of AURORA CCF2 Fluorescence Disclosing Substrate Solutions:

Prepared four separate solutions of 2 mL each for each plate using the amounts recited in Table 2 below according to the following procedure.

Added Reagent A to 50-mL tube first, then added Reagent B. Mixed. Then added Reagent C. Mixed.

Table 2. Substrate Formulation Instructions		
(Reagent A +	Reagent B)	+ Reagent C
6 $\mu\text{L}$	60 $\mu\text{L}$	1 mL
24 $\mu\text{L}$	240 $\mu\text{L}$	4 mL
48 $\mu\text{L}$	480 $\mu\text{L}$	8 mL
60 $\mu\text{L}$	600 $\mu\text{L}$	10 mL
2 mL/plate, 20 $\mu\text{L}$ /well; make 2 mL extra		

Incubation after addition of the AURORA CCF2 fluorescence disclosing solution: 1 hour at room temperature in the dark

Spectrophotometric analysis: CYTOFLUOR (Millipore Corporation, Bedford, Massachusetts) 2 instruments using the following wavelengths in nanometers. Excite 395 Emit 460 (Blue) and Excite 395 Emit 530 (Green)

(v) Calculation of Data

	BKG Blue (BB)	= Average reagent background blue emission.
10	BKG Green (BG)	= Average reagent background green emission.
	Corrected Blue (CB)	= Subtract BB from all blue readings on plate.
	Corrected Green (CG)	= Subtract BG from all green readings on plate.
15	Blue/Green Ratio (BGR)	= Divide CB by CG (CB/CG).
	BGRF	= Divide BGR by BGR of USC wells.
	Maximum Activity	= Average of BGRF of stimulated cells (TNF- $\alpha$ max or IL-1 $\beta$ max).
20	% Inhibition of T Maximum Activity = (100 - (average BGRF of unknown (cells + inhibitor)/TNF- $\alpha$ max or IL- $\beta$ max) $\times$ 100).	

Representative sulfonylaminocarbonyl derivatives useful in the present invention were tested at a concentration of 10  $\mu$ M for the ability to inhibit NF- $\kappa$ B mediated transcription using the method described above, and the results are shown below in Table 3 in the column labeled "Percent inhibition at 10  $\mu$ M."

TABLE 3. Inhibition of NF- $\kappa$ B Mediated Transcription  
(Page 1 of 9)

Example No.	Percent Inhibition at 10 $\mu$ M
1	24.83
2	37.20
3	79.34
4	35.32
5	56.40
6	64.92
7	37.04
8	<10 <sup>a</sup>
9	33.15
10	39.74
11	50.11
12	57.02
13	<10
14	13.84
15	12.56
16	<10
17	43.76
18	35.92
19	20.24
20	<10
21	29.41
22	20.17
23	38.67
24	30.97
25	33.24
26	32.80
27	26.15
28	30.20
29	38.49

Table 3. Inhibition of NF- $\kappa$ B Mediated Transcription  
(Page 2 of 9)

Example No.	Percent Inhibition at 10 $\mu$ M
30	52.05
31	74.02
32	20.33
33	58.63
34	24.30
35	<10
36	51.23
37	<10
38	31.49
39	<10
40	<10
41	<10
42	<10
43	70.23
44	<10
45	53.50
46	34.79
47	41.89
48	13.77
49	22.93
50	39.06
51	47.24
52	<10
53	61.31
54	<10
55	55.07
56	<10
57	20.38
58	<10

Table 3. Inhibition of NF- $\kappa$ B Mediated Transcription  
(Page 3 of 9)

Example No.	Percent Inhibition at 10 $\mu$ M
59	<10
60	<10
61	27.45
62	<10
63	23.03
64	55.44
65	16.44
66	<10
67	13.82
68	34.32
69	75.49
70	<10
71	<10
72	14.11
73	<10
74	37.58
75	<10
76	<10
77	<10
78	40.90
79	<10
80	<10
81	<10
82	<10
83	10.58
84	44.82
85	44.99
86	16.00
87	<10

Table 3. Inhibition of NF- $\kappa$ B Mediated Transcription  
(Page 4 of 9)

Example No.	Percent Inhibition at 10 $\mu$ M
88	<10
89	31.94
90	13.55
91	39.69
92	<10
93	14.51
94	<10
95	33.07
96	10.70
97	<10
98	<10
99	<10
100	50.03
101	<10
102	20.58
103	<10
104	<10
105	<10
106	72.28
107	<10
108	<10
109	51.35
110	15.48
111	<10
112	<10
113	<10
114	<10
115	38.99
116	<10

Table 3. Inhibition of NF- $\kappa$ B Mediated Transcription  
(Page 5 of 9)

Example No.	Percent Inhibition at 10 $\mu$ M
117	<10
118	<10
119	56.56
120	54.98
121	<10
122	65.26
123	<10
124	11.32
125	11.04
126	10.02
127	74.01
128	<10
129	<10
130	<10
131	33.39
132	<10
133	<10
134	18.39
135	<10
136	<10
137	<10
138	66.16
139	65.52
140	38.70
141	<10
142	53.87
143	65.81
144	16.19
145	<10

Table 3. Inhibition of NF- $\kappa$ B Mediated Transcription  
(Page 6 of 9)

Example No.	Percent Inhibition at 10 $\mu$ M
146	28.31
147	<10
148	<10
149	<10
150	<10
151	<10
152	<10
153	<10
154	77.73
155	<10
156	<10
157	<10
158	25.90
159	10.14
160	34.22
161	51.45
162	75.35
163	62.44
164	55.18
165	28.67
166	<10
167	40.01
168	39.14
169	21.31
170	78.57
171	62.23
172	86.90
173	36.94
174	32.24



Table 3. Inhibition of NF- $\kappa$ B Mediated Transcription  
(Page 7 of 9)

Example No.	Percent Inhibition at 10 $\mu$ M
175	<10
176	<10
177	63.60
178	<10
179	<10
180	91.96
181	<10
182	69.81
183	<10
184	21.20
185	73.94
186	18.83
187	57.76
188	50.76
189	15.06
190	27.56
191	55.66
192	63.94
193	38.28
194	89.85
195	91.77
196	73.11
197	<10
198	75.78
199	50.73
200	72.66
201	87.14
202	25.39
203	52.22

Table 3. Inhibition of NF- $\kappa$ B Mediated Transcription  
(Page 8 of 9)

Example No.	Percent Inhibition at 10 $\mu$ M
204	70.04
205	11.72
206	47.89
207	60.34
208	22.39
209	56.80
210	52.45
211	24.65
212	60.24
213	19.73
214	71.74
215	74.72
216	65.43
217	37.08
218	<10
219	15.15
220	65.49
221	44.70
222	<10
223	68.21
224	<10
225	26.39
226	46.34
227	77.28
228	76.08
229	75.79
230	75.15
231	78.10
232	76.92

Table 3. Inhibition of NF- $\kappa$ B Mediated Transcription  
(Page 9 of 9)

Example No.	Percent Inhibition at 10 $\mu$ M
233	76.94
234	76.65
235	145.92
236	79.42
237	57.13
238	12.0
239	<10
240	10.3
241	<10
242	<10
243	<10
244	<10
245	16.1
246	<10
247	14.8
248	11.4
249	<10
250	<10

<sup>a</sup> “<10” means percent inhibition was greater than 0  $\mu$ M but less than 10  $\mu$ M.

As shown by cell-based assay data, the sulfonylaminocarbonyl derivatives in Table 3 are inhibitors of NF- $\kappa$ B mediated transcription that are able to cross cell membranes and reach a target in a NF- $\kappa$ B signal pathway. Accordingly, the sulfonylaminocarbonyl derivatives are useful in the present invention for treating a disease or a disorder responsive to the inhibition of NF- $\kappa$ B such as, for example, rheumatoid arthritis and osteoarthritis, autoimmune diseases, psoriasis, asthma, cardiovascular diseases such as, for example, atherosclerosis, acute coronary syndromes including myocardial infarction and unstable angina, and congestive

heart failure, Alzheimer's disease, multiple sclerosis, cancer, type 2 diabetes, metabolic syndrome X or inflammatory bowel disease (IBD).

In carrying out the methods for treating a disease or a disorder responsive to the inhibition of NF- $\kappa$ B of the present invention, sulfonylaminocarbonyl derivatives useful in the present invention may be administered in a number of pharmaceutically acceptable oral and parenteral forms. Thus, the sulfonylaminocarbonyl derivatives can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the sulfonylaminocarbonyl derivatives can be administered by inhalation, for example, intranasally. Additionally, the sulfonylaminocarbonyl derivatives can be administered transdermally. The following dosage forms may comprise as the active component a compound of Formula I or Formula II, or another sulfonylaminocarbonyl derivative useful in the present invention, or a pharmaceutically acceptable salt thereof.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets

and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted, and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or, synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 100 mg preferably 0.5 mg to 100 mg according to the

particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

In therapeutic use as antagonists or as agents for the treatment of diseases, the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg/kg daily. A daily dose range of about 0.01 mg to about 10 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, the compound being employed.

Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.

Examples of pharmaceutical preparations of the sulfonylaminocarbonyl derivatives useful in the present invention are described below. Such preparations can be administered to a patient, including a human, from 1 to 6 times a day for treatment of diseases and disorders responsive to inhibition of NF- $\kappa$ B mediated transcription.

#### FORMULATION EXAMPLE 1

##### Tablet Formulation:

Ingredient	Amount (mg)
Compound of Example 199	25
Lactose	50
Cornstarch (for mix)	10
Cornstarch (paste)	10
Magnesium stearate (1%)	5
Total	100

The compound of Example 199, lactose, and cornstarch (for mix) are blended to uniformity. The cornstarch (for paste) is suspended in 200 mL of water

and heated with stirring to form a paste. The paste is used to granulate the mixed powders. The wet granules are passed through a No. 8 hand screen and dried at 80°C. The dry granules are lubricated with the 1% magnesium stearate and pressed into a tablet.

5

#### FORMULATION EXAMPLE 2

##### Coated Tablets:

The tablets of Formulation Example 1 are coated in a customary manner with a coating of sucrose, potato starch, talc, tragacanth, and colorant.

#### FORMULATION EXAMPLE 3

10

##### Injection vials:

The pH of a solution of 500 g of the compound of Example 3 and 5 g of disodium hydrogen phosphate is adjusted to pH 6.5 in 3 L of double-distilled water using 2 M hydrochloric acid. The solution is sterile filtered, and the filtrate is filled into injection vials, lyophilized under sterile conditions, and aseptically sealed. Each injection vial contains 25 mg of the compound of Example 3.

15

#### FORMULATION EXAMPLE 4

##### Suppositories:

A mixture of 25 g of the compound of Example 31, 100 g of soya lecithin, and 1400 g of cocoa butter is fused, poured into molds, and allowed to cool. Each suppository contains 25 mg of the compound of Example 31.

20

#### FORMULATION EXAMPLE 5

##### Solution:

A solution is prepared from 1 g of the compound of Example 55, 9.38 g of  $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$ , 28.48 g of  $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$ , and 0.1 g benzalkonium chloride in 940 mL of double-distilled water. The pH of the solution is adjusted to pH 6.8 using 2 M hydrochloric acid. The solution is diluted to 1.0 L with double-distilled water, and sterilized by irradiation. A 25 mL volume of the solution contains 25 mg of the compound of Example 55.

25

FORMULATION EXAMPLE 6

Ointment:

500 mg of the compound of Example 119 is mixed with 99.5 g of petroleum jelly under aseptic conditions. A 5 g portion of the ointment contains 25 mg of the compound of Example 119.

FORMULATION EXAMPLE 7

Capsules:

2 kg of the compound of Example 180 are filled into hard gelatin capsules in a customary manner such that each capsule contains 25 mg of the invention compound.

FORMULATION EXAMPLE 8

Ampoules:

A solution of 2.5 kg of the compound of Example 231 is dissolved in 60 L of double-distilled water. The solution is sterile filtered, and the filtrate is filled into ampoules. The ampoules are lyophilized under sterile conditions and aseptically sealed. Each ampoule contains 25 mg of the compound of Example 231.

Having described the methods of the present invention above, embodiments of the present invention are hereupon claimed.